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1 Macromolecular crystallography 
1.1 History of crystallography 
To start this historical introduction, the term “crystallography” should be defined. 
It was first introduced in the 18th century by the Swiss savant Maurice-Antoine Capeller 
as the study at the atomic scale of substances able to form crystals1. The word itself is 
based on the Latin crystallus for crystal and graphie for writing. The crystal order was 
later defined by the French physicist Auguste Bravais in the 19th century as a repetition, 
by translation, in three dimensions of an elementary motif. He is known for the 
conception of Bravais lattices and the formulation of Bravais law. The next major event 
was the discovery of a fundamental element of X-ray crystallography: X-rays, 
discovered by the German physicist Wilhelm Conrad Röntgen in 1895. The German 
physicist Max von Laue later discovered X-ray diffraction by crystals and was awarded 
a Nobel Prize in 1914. This event was commemorated in 2014 by the International 
Year of Crystallography (IYCr2014) by the United Nations to emphasize the 
importance of crystallography in physics, chemistry and medicine. Laue’s award was 
directly followed by the Nobel Prize to William Henry and William Lawrence Bragg in 
1915 for “their services in the analysis of crystal structure by means of X-rays”. In a 
non-exhaustive list, several works in crystallography have contributed substantially to 
the biological field: the first diffraction pattern of a protein crystal (pepsin) by Dorothy 
Crowfoot Hodgkin and John Desmond Bernal in 1934 (Bernal & Crowfoot, 1934), the 
elucidation of the double-helix structure of DNA by Rosalind Franklin, Francis Crick 
and James Watson in 1953 (Watson & Crick, 1953) and the first protein structures 
(myoglobin and hemoglobin) elucidated by X-ray crystallography by John Kendrew and 
Max Perutz in 1958-60 (Kendrew et al. 1958; Perutz et al. 1960). In the field of protein 
synthesis or translation, crystallography also contributed to the understanding of the 
process by elucidating several important structures. Among them are the structure of 
the first tRNA, aminoacyl-tRNA synthetase and CCA-adding enzyme, a tRNA 
maturation enzyme. They were respectively solved by groups headed by Alexander 
                                                 
1 https://www.afc.asso.fr/qu-est-ce-que-la-cristallographie/histoire 
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Rich and Aaron Klug in parallel in 1973-74 (Kim et al. 1973; Robertus et al. 1974), Irwin 
in 1976 (Irwin et al. 1976) and Thomas Steitz in 2002 (Li et al. 2002). More recently, 
the Nobel Prize 2009 was awarded for “studies of the structure and function of the 
ribosome” to Venkatraman Ramakrishnan, Thomas Steitz and Ada Yonath. All these 
discoveries are summarized in Figure 1-1. 
 
Figure 1-1 : Chronology of selected discoveries related to X-ray crystallography. Pictures are 
all in the public domain or from Wikipedia. 
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Since more than half a century, macromolecular crystallography is the method 
of choice for structural characterization of biological macromolecules, fundamental and 
applied research, such as drug development. At the end of summer 2018, the 
worldwide repository Protein Data Bank (PDB) contained more than 140,000 deposited 
structures of proteins and nucleic acids, with more than 80% determined by X-ray 
crystallography. As of today, crystallography is involved in a great variety of disciplines: 
physics, chemistry, mathematics, biophysics, biology, medicine, material sciences, 
metalworking industry and earth sciences. It finds applications in almost all scientific 
fields. When crystals are available, X-ray crystallography is the quickest and most 
powerful method for structural analysis. A complete dataset can nowadays be collected 
within minutes, if not seconds, resolutions down to 0.48 Å are accessible with proteins, 
as for crambin (Schmidt et al. 2011) or for an iron-sulfur protein (Hirano et al. 2016), 
and structures of high molecular weight macromolecules can be elucidated, such as 
the ribosome.  
Crystallogenesis was recently introduced as the discipline which focuses on 
crystal growth. The aim of this discipline is not only to grow crystals for analysis but 
also to understand the processes involved behind crystal growth and nucleation, in 
order to better control them. This field is multidisciplinary and brings together 
specialists from various fields such as physicists, chemists and biologists. The fathers 
of crystallogenesis are Richard Giegé and Alexander McPherson, well known for their 
respective reference books, “Crystallization of Nucleic Acids and Proteins” (Ducruix 
and Giegé 1992) and “Introduction to Macromolecular Crystallography” (McPherson 
2009).  
 
1.2 Crystallographic analysis 
The structural analysis by crystallography of a macromolecule, defined as 
proteins, nucleic acids and their complexes, includes several steps: purification, 
crystallization, X-ray analysis and 3D structure determination. As illustrated in Figure 
1-2, the first step in a structural study of a biological macromolecule by crystallography 
is the production, purification and quality control of the sample of interest. By quality is 
meant the assessment of purity and integrity, homogeneity, activity and stability in 
solution, parameters which were shown to be critical in crystal formation (Giegé et al. 
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1986; Raynal et al. 2014). These are usually assessed by the use of diverse and 
complementary methods e.g. SDS-PAGE, Dynamic Light Scattering (DLS), Size 
Exclusion Chromatography (SEC) and activity assay. The way to obtain crystals is still 
nowadays mostly empirical and therefore the result of trial and error experiments. 
Hundreds of combinations of diverse crystallizing agents, buffers at different pH and 
additives, are tried in a variety of methods, from simple batch, vapor diffusion to 
counter-diffusion. But trying more crystallization conditions, beyond a few hundreds, 
does not necessarily increase in the number of useful hits (Newman et al. 2005; 
Newman 2011). Instead, complementary and/or advanced methods have been 
developed to facilitate crystal detection, to increase success rate at screening stage or 
to study the formation of nuclei to select conditions favoring crystallization, such as 
trace fluorescent labeling (TFL) (Pusey et al. 2015), microseed matrix screening 
(MMS) (D’Arcy et al. 2007, 2014), microfluidic chips (Pinker et al. 2013) or the use of 
Tb-Xo4 (Engilberge et al. 2017). These methods will be presented and discussed in 
this thesis.  
 
 
 
Figure 1-2 : Illustration of the four major steps in the structural study by crystallography of a 
biological macromolecule: purification, crystallization, X-ray analysis and 3D structure 
determination (adapted from Claude Sauter). 
 
X-ray analysis of the crystals can then be performed with several types of 
instrumentations: laboratory diffractometers (in-house sources) using rotating-anodes, 
microfocus sealed tube or the metal-jet technology as X-ray sources (Skarzynski 2013) 
or bigger infrastructures like synchrotrons or X-ray free electron lasers (XFEL). This 
step consists of collecting hundreds to thousands of diffraction images while the crystal 
is rotated in the X-ray beam. 
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The final step, 3D structure determination, is then performed thanks to the use 
of a combination of program packages running on personal computers or web-servers, 
for example XDS (Kabsch 2010), PHENIX (Adams et al. 2010) or CCP4 (Winn et al. 
2011) which enable the processing of diffraction data, then structure solution, 
refinement and analysis.  
Two main bottlenecks in this workflow are first the determination of reproducible 
crystallization conditions and second the conditioning of crystals for X-ray analysis. 
Partial solutions and helps lie in the use of unconventional methods or devices. Some 
of them will be discussed in this thesis, and involve microfluidic chips ChipX, the Xtal 
Controller instrument, or advanced nucleation methods. 
1.3 Phase diagram 
The process of crystallization can easily be visualized using a phase diagram. 
The phase diagram shown Figure 1-3 represents the state of a macromolecule in a 
solution and is usually represented by a 2D scheme, with the crystallizing agent 
concentration on the X-axis and the macromolecule concentration on the Y-axis. The 
diagram contains two areas separated by the solubility curve: the soluble zone under 
the curve where the macromolecule is undersaturated and fully soluble, and the 
supersaturated region above the curve, in which the macromolecule is in a 
thermodynamical unstable state being in excess and pushed to leave the solution. The 
latter region can be divided in three zones: (i) the metastable zone, where 
supersaturation is low, not high enough to cross the energy barrier and form nuclei 
(see section 1-4-1), (ii) the nucleation zone, where supersaturation is sufficient to 
induce ordered clusters, nuclei, of proteins to form in the solution, and (iii) the 
precipitation zone, where supersaturation reached such a high level that 
macromolecules will rapidly aggregate in a non-ordered manner. The actual pathway 
through the phase diagram for crystallization admitted by the scientific community 
consists in crossing the solubility curve to reach the nucleation zone, to form a nucleus, 
before driving the system back to the metastable zone for crystal growth. 
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Figure 1-3 : Schematic representation of the salting-out phase diagram. The X and Y-axis 
represent the crystallizing agent and macromolecule concentrations, respectively. Each color 
represents a different zone indicated on the right, as well as the solubility curve.   
 
The first condition needed for crystallization is to reach a supersaturation state 
by crossing the solubility curve. This is possible by increasing either molecule or 
crystallant concentrations, or both at the same time. The macromolecule solubility 
curve can be shifted by environmental conditions, such as pH, temperature or 
contaminants in solution. In the supersaturated state, the solution will not remain 
homogeneous (Asherie 2004). Small chemicals, e.g. inorganic salts, will crystallize 
after only an increase of supersaturation of few percents, in opposition to biological 
macromolecules, which need to exceed the solubility from hundred to a thousand 
percent (Chernov 1997), to reach high supersaturation and high nucleation rate 
probability to ensure crystallization in a reasonable amount of time. This fact is 
observable by the rapid and regular growth of salt crystals during crystallization trials 
with biological macromolecules. To avoid accumulation of a too high number of nuclei 
and no observable crystal (due to their small size), the solution then needs to enter 
back the metastable zone. This movement is made possible by the reduction of the 
number of molecules available in the solution following nucleation and the start of 
crystal growth. In this zone, a lower supersaturation prevents the formation of new 
nuclei but still allows the growth of existing nuclei in observable crystals. 
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In the following, the description of the phase diagram and of crystallization 
techniques will be limited to the ones which are relevant for biological macromolecules, 
such as proteins and nucleic acids.  
 
1.4 Macromolecular crystallization process 
1.4.1 Nucleation 
Three steps in macromolecular crystals formation are widely accepted: 
nucleation, crystal growth and termination. The first often being considered as the most 
limiting, the second is important for crystal quality and the last for final crystal size 
(McPherson and Kuznetsov 2014). How nucleation occurs is still controversial and no 
unique model is applicable to every crystallization experiments. The first model is the 
classical nucleation theory, or one-step nucleation pathway (Figure 1-4), which was 
firstly described in 1926 (Volmer and Weber 1926) and adapted for macromolecule 
crystal nucleation in 1935 (Stranski and Kaischew 1935).  
 
 
 
Figure 1-4 : Classical nucleation theory or one-step nucleation pathway for macromolecular 
crystals. The roman numerals represent state transitions, the box represents a growing crystal. 
 
In this classical nucleation theory, small reversible clusters are formed in 
supersaturation conditions (I). As long as they do not exceed a certain critical size, 
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they remain transient and prone to dissolve. If they exceed this size, they will grow into 
crystals (II), alimented by soluble macromolecules (III) or even aggregates. 
 
 
 
Figure 1-5 : Graphical representation of the supersaturation implication in the one-step 
nucleation process. The X-axis represents the radius R of the molecular assemblies forming in 
solution and the Y-axis the free energy ΔG for formation of the crystalline assembly. Rc 
represents the critical size for formation of a crystalline assembly at a given supersaturation, 
ΔGc the free energy at Rc. At higher supersaturation (situation 1) the induction energy and 
critical nucleus size are smaller than at lower supersaturation (situation 2). 
 
In the supersaturated zones, macromolecules will form assemblies of different 
types, which form and dissolve at different rates, depending on the supersaturation 
level. The radius R of these assemblies must reach a critical size, called here Rc, at 
which further assembly, and thus crystal growth, will be energetically more favorable 
than remaining in solution (Figure 1-5). Crystal formation is dependent on 
supersaturation state and speed in which supersaturation is reached (García-Ruiz 
2003). To illustrate this dependency on the supersaturation level, a high 
supersaturation (1) and a low supersaturation states (2) are indicated in Figure 1-5. At 
higher supersaturation (1), a smaller minimum size Rc1 and a lower free energy ΔGc1 
is needed to transform an amorphous assembly, or cluster, into a crystalline one.  
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A second model is the two-step nucleation pathway (Figure 1-6). In this model, 
a metastable intermediate phase, or MIP (I), forms in the supersaturated solution 
before formation of a more ordered nucleus inside the MIP (II). This nucleus will then 
grow with the help of the surrounding macromolecules from the MIP (III) and from the 
soluble ones (IV).   
 This two-step pathway was observed in the nucleation of several protein 
crystals, among which are the lumazine synthase (Olga Gliko et al. 2005) or the beta-
lactoglobulin (Sauter et al. 2015). Until now, there is no evidence that both theories 
could not coexist. 
 
 
 
Figure 1-6 : Two-step nucleation pathway for macromolecular crystals. The roman numerals 
represent state transitions, boxes represent a nuclei or a growing crystal. 
  
A method of choice to observe nucleation, early crystal growth and compare the 
effect of different crystallant solutions is dynamic light scattering and will be presented 
latter.  
1.4.2 Growth and termination 
Crystal growth and termination are more defined and accepted in the 
community. Atomic force microscopy (AFM) was introduced to study crystal growth in 
situ. It allowed the visualization of biological crystal growth in layers and revealed two 
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distinct mechanisms: tangential and face normal growth (Figure 1-7). Tangential 
growth occurs at the edge of existing layers and is responsible for their extension over 
the crystal surface. Face normal growth consists of the deposition or the formation of 
a new nucleus on an existing layer (or crystal face). This second mechanism must 
overcome an energy barrier, and thus, is limiting in comparison to tangential growth 
(reviewed in McPherson and Kuznetsov, 2014).  
 
 
Figure 1-7 : Representation of the two crystal growth ways: tangential and face normal growth 
(adapted from McPherson and Kuznetsov, 2014). 
 
An additional tangential growth mechanism was described and is called screw 
dislocation (McPherson et al. 2003). This mechanism is presented in Figure 1-8 and 
based on the growth of an existing layer but in a circular manner due to a dislocation. 
This results in a continuous layer growing on itself. 
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Two reasons are presented in the literature (McPherson et al. 2001) to explain 
termination of growth of a macromolecule crystal. First, the reduction of molecules 
available in solution as they are massively joining the growing crystal. Their 
concentration in solution drops to a point where it is no longer sufficient to sustain 
crystal growth. In other words, the system will leave the supersaturated zone and reach 
the thermodynamic equilibrium on the solubility curve. Second, the accumulation of 
impurities, in form of denatured molecules, aggregates or foreign molecules, at the 
surface of the growing crystals, a phenomenon known as face poisoning. The first 
case, the limited availability of macromolecules can be easily solved by constantly 
providing new macromolecules to the solution. In opposition, the second case is more 
difficult to solve, but it was shown by McPherson et al. in 2001 to be feasible by 
scraping the surface of a crystal and thus reviving its growth.  
Macromolecule crystals are very fragile, they easily break when touching them 
and are sensible to temperature and pH. One of the main reasons for this is their high 
solvent content. Crystals of macromolecules exhibit solvent content between 30% and 
80% in most cases, with the majority around 50% (Weichenberger et al. 2014, 2015). 
This solvent content is mostly due to the irregular form of macromolecules, not allowing 
a very tight crystal packing and the low amount of direct crystal stacking contacts 
between macromolecules. Additional contacts are performed via water molecule 
bridges.  
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1.5 Macromolecular crystallization methods 
To induce crystal growth, several crystallization methods are available. The 
principle of the usual crystallization techniques and their expected pathways through 
the phase diagram are described in Figure 1-9 and Figure 1-10.  
 
 
Figure 1-9 : Schematic representations of usual crystallization techniques: a) batch, b) vapor 
diffusion, c) dialysis, d) free-interface diffusion (FID) and e) counter-diffusion. The red 
compartments represent the macromolecular solutions, the grey ones the crystallizing agent 
solutions (excepted when indicated) (adapted from Sauter et al., 2001).  
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Figure 1-10 : Schematic representation of crystallization trajectories in the phase diagram. The 
X and Y-axis represent crystallizing agent and macromolecule concentrations, respectively. 
Colors represent different zones indicated on the right and the solubility curve separates the 
under- and supersaturated regions. Each pathway in the diagram is associated with a letter, 
which refers to a crystallization technique: a) batch, b) vapor diffusion, c) dialysis, d) free-
interface diffusion and e) counter-diffusion. 
The batch method (a) is the easiest one. It consists in mixing the macromolecule 
solution with the crystallization agent. The mix is incubated until crystal growth is 
observed. The associated pathway in the phase diagram is very simple: if the 
nucleation zone was reached by the mix, the solution will travel down the Y-axis as the 
drop volume remains constant but macromolecules will leave the soluble phase. If no 
supersaturated zone was reached, the mix will stay soluble and no evolution will occur. 
Vapor diffusion (b) is the most widely used method. It allows a gradual concentration 
of the drop, which is a mix of the macromolecule and crystallization agent solutions. 
This concentration occurs in a closed environment and is induced by the diffusion of 
water from the drop to the reservoir. This diffusion is explained by the differences of 
crystallization agent concentration (and related vapor surface tension) between the 
drop and the reservoir. In the phase diagram, this method will result in an increase 
along both X and Y-axis (as the drop volume goes down in most cases) and travel 
towards the supersaturated zones, where aggregates or nuclei will form. In dialysis (c), 
a membrane with calibrated pores only permeable to the crystallizing agent is used to 
separate the macromolecule and the reservoir solutions. As the solution volume 
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remains constant and only the crystallizing agent concentration can increase, the 
movement in the phase diagram will be horizontal until nucleation is reached. In the 
diffusion at the interface (d), or free interface diffusion (FID), both macromolecule and 
crystallizing agent solutions are brought into contact in a recipient small enough to 
avoid convection. In this condition, both solutions will gently mix by diffusing towards 
each other through a virtual interface. In opposition to dialysis, the macromolecule 
concentration will diminish (as the volume is increased) and crystallization agent 
concentration will increase. This will be characterized in the phase diagram by an 
increase in the X-axis and a decrease in the Y-axis into the supersaturation zones. The 
last method described here is counter diffusion (e). It requires a long capillary to create 
a gradient of crystallizing agent concentration and of supersaturation along the 
recipient by diffusion, thus continuously scanning different conditions. One capillary 
may be equivalent to many drops in batch or vapor diffusion. Several trajectories 
generated by the gradient along the capillary are represented in the phase diagram for 
this technique. Among counter-diffusion setups, one can mention crystallization chips 
including the microfluidic chips ChipX developed by Claude Sauter (Pinker et al. 2013) 
which will be described later in this thesis. 
There are practical advantages that make some methods more widely used, 
such as vapor diffusion thanks to its easy up scaling in terms of number of assays. 
However, in some cases it is interesting to combine several of them and this case will 
be illustrated below in chapter III. 
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2 Advanced crystallization techniques 
As presented above, crystallization of a macromolecular target is still nowadays 
the result of a trial and error experiments. In the history of bio-crystallography, methods 
were developed to increase crystallization success rate, crystal size and quality, and 
efforts were made to find a universal crystallizing agent. Some methods aim at favoring 
nucleation in solution, such as the use of the nucleant Tb-Xo4 (Engilberge et al. 2017), 
nanoporous materials (Shah et al. 2012) or crystallization assays exploiting an 
unconventional environment like agarose gel (Lorber et al. 2009), counterdiffusion 
(García-Ruiz 2003; Otálora et al. 2009), microfluidic (Sauter et al. 2007) or microgravity 
(Ng et al. 2002; Vergara et al. 2005). Other methods are based on the transfer of 
existing nuclei or crystal pieces in a fresh crystallization assay to favor crystal growth 
in the new solution, such as the use of animal hairs (cat, horse, human) or microseed 
matrix screening (MMS) (D’Arcy et al. 2007, 2014). In addition to favor nucleation or 
crystal growth, methods were also developed to make detection of nucleation events 
or crystals easier, such as depolarized dynamic light scattering (DDLS) (Schubert et 
al. 2015), as well as to facilitate discrimination between salt and protein crystals, for 
example by the use of trace fluorescent labeling (TFL) (Pusey et al. 2015). 
 
2.1 Methods to favor nucleation and crystal growth 
2.1.1 The Tb-Xo4 molecule 
The lanthanide complex called “crystallophore” (Xo4) containing terbium (Tb) is 
a small molecule which presents several advantages in a crystallography study: it is a 
powerful phasing agent thanks to Tb anomalous properties, it acts as a nucleating 
agent by building bridges between proteins, and can be detected under UV-illumination 
to better distinguish macromolecule crystals (Engilberge et al. 2017).  
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Figure 2-1 : The nucleant Tb-Xo4 and its effect on crystallization. A) Chemical structure of Tb-
Xo4. B) 3D representation of Tb-Xo4. C) Comparison of crystal size and habit under strictly 
similar conditions for the two proteins of unknown structures pb6 (protein of the T5 phage tail) 
and MDH (malate dehydrogenase), in the absence and in the presence of 10 mM of Tb-Xo4 
(adapted from Engilberge et al., 2017, 2018). 
 
As illustrated in Figure 2-1 Tb-Xo4 is a small molecule used as an additive. It 
can be stored as a powder and dissolved with the macromolecule solution prior to 
crystallization assays. The nucleating property of this complex was shown for several 
target proteins: Tb-Xo4 can increase the crystal quality when conditions are already 
known and help finding new conditions, as illustrated for pb6 and MDH (Figure 2-1). 
In Engilberge et al., 2017, the authors even determined the crystallization diagram of 
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hen egg white lysozyme (HEWL) in the absence and in the presence of Tb-Xo4 and 
demonstrated a clear effect of the molecule on crystal formation at low concentrations 
of both protein and crystallizing agent.   
 
2.1.2 Crystallization in unconventional environments 
The Grashof number NG allows to estimate the balance between convection and 
diffusion in a defined environment by measuring the ratio between buoyancy driven 
convection (due to two liquids/elements of different density) and diffusion. The aim of 
a variety of methods involving unconventional environments is to reduce this value 
(Carter and Sweet 1997). The underlying idea is to reduce the Grashof number NG in 
order to reduce convection in the crystallization environment and associated crystal 
growth defects. The smaller this value, the higher the influence of diffusion to drive 
particle transport in the solution. As presented in section 1.4, during crystal growth 
macromolecules surrounding the crystal will attach to its surface, thus creating a 
gradient of macromolecule concentration in the neighboring solution. In a conventional 
environment (a liquid vapor diffusion drop for instance), uncontrolled convective 
movements will take place due to the concentration (and density) differences. If a 
convection-free environment can be reached (for example in a capillary or in a 
microfluidic channel of small section, typically < 100 µm), the only force driving 
particles’ movement inside the solution will be diffusion. Reduction or absence of 
convection was shown to enhance crystal quality by minimizing crystal defects (Lorber 
et al. 1999). 
The Grashof number is defined as following: 
 
NG = g x ρ(δρ/δc) x Δc x d3 x μ-2 
 
where g is the gravity value, ρ the density of the fluid, δρ/δc the density gradient in the 
solution due to the concentration differences, Δc the difference in concentration for 
example around a growing crystal, d the smallest dimension of the system (i.e. the 
crystallization chamber) and μ the viscosity of the medium (Carter and Sweet 1997)). 
To reduce the value of NG, several parameters can be tuned: g, (δρ/δc), d and 
μ. Modifying the density gradient is difficult in practice and is not of major impact. The 
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gravity value can be modified by performing micro- or zero-gravity experiments (Ng et 
al. 2002). This can reduce the NG value by a factor of 104 to 106. Increase of the 
viscosity in the solution, which is to the second power in the equation, can be 
performed by addition of viscous compounds into the solution, such as low 
concentrations of agarose (Garcıá-Ruiz et al. 2001), polyethylene glycol (PEG) or 
dextran (unpublished work from Bernard Lorber). But this is limited by the maximum 
viscosity that can be pipetted and correspond to about 10 times the viscosity of water, 
thus maximally reducing the NG value by a factor of 100. In contrast, the smallest 
dimension of the system is a very interesting parameter, as it appears to the third power 
in the equation and is relatively easy to modify. The reduction in the volume of droplets 
(a few µL to 100 nL), and thus their diameter (from 2.7 mm for a 5 µL drop to 0.8 mm 
for a 100 nL drop), by the development of pipetting robots in the past decades already 
reduced this parameter. But in vapor diffusion assays, evaporation of the solution at 
the surface also induces convection. The use of capillaries or a microfluidic device 
further reduces the size of the crystallization chamber, down to 100 µm and below, and 
thus reducing the NG value by a factor of 103 compared to 100 nL droplets. Agarose 
gel can also be added to the solution, its fiber network forming even smaller pores and 
reducing the NG value by a factor of 105 (Gavira and García-Ruiz 2002). Another 
advantage of capillaries, microfluidic devices and agarose gel is to avoid 
sedimentation, which would induce movements in the solution and generate stacks of 
intertwined crystals.   
 
2.1.3 Seeding techniques 
Seeding is a common practice in material science to grow large crystals. The 
rationality behind seeding is to by-pass the nucleation energetic barrier by providing 
nuclei or small crystals into a mother liquor which is already supersaturated, but in the 
metastable zone of the phase diagram (i.e. a zone not favorable to spontaneous 
nucleation). The first method used in biological crystallization was the transfer of 
macro-crystals, which was followed by the use of animal hairs to transfer small pieces 
of crystal from one drop to another to favor crystallization. The principle was to rub a 
hair over a crystal, thus removing small crystal parts and storing them on hair asperities 
and transferring them to a new drop. A drawback of this technique was that it was time 
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consuming when setting up hundreds of drops manually, in order to perform screening 
for instance. The situation was improved using pipetting robots which led to the 
development of MMS. 
 
 
Figure 2-2 : Illustration of crystal morphology improvement by MMS. A) Crystals of serine 
protease grown in 30% (w/v) PEG 3350, 0.1 M Tris-HCl pH 8.5 used to prepare seed stock. B) 
Optimized crystals of serine protease grown in 30% (w/v) PEG 3350, 0.2 M magnesium 
chloride, 0.1 M Tris–HCl pH 8.5 after MMS with the crystals from A). C) These small, 
unpromising crystalline aggregates of a serine protease complexed with a natural product 
inhibitor were grown in 20% (w/v) PEG 10 000, 0.1 M Tris–HCl pH 8.5 and used to make a 
seed stock. D) Optimized crystals of the same complex after MMS with the seed stock from the 
original conditions. The final conditions were 25% (w/v) PEG 3350, 0.2 M lithium sulfate, 0.1 
M HEPES pH 7.5 (adapted from D’Arcy et al., 2014).  
 
MMS is based on the systematic introduction of small crystal pieces, or even 
nuclei, in a crystallization screen. Crystals, even of poor quality (in diffraction limit 
and/or morphology) are crushed by means of beads or a pipet tip to produce what is 
called a seed stock. This resulting suspension can be used in different dilutions in a 
screening assay. This method was shown to increase the number of hits obtained 
during screening and to improve crystal quality (D’Arcy et al. 2007, 2014). It can indeed 
be used to improve quality of existing crystals, find new crystallization conditions and 
identify new crystal forms of the same macromolecule (as illustrated in Figure 2-2) or 
even to crystallize structurally-related proteins. This latter procedure is called cross-
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seeding. Although it presents a lower success rate compared to regular MMS, it may 
be used when no crystallization conditions were found by screening but crystals of an 
homologous protein are available. The power of MMS is to enable the exploration of 
the metastable zone of the phase diagram (not only the nucleation zone) by providing 
nuclei or small crystals into crystallization assays. Hence, all conditions that are already 
supersaturated, even if they would stay clear for a while without seed, may be activated 
by seeding and yield crystals.   
 
2.2 Methods to detect nucleation and crystal growth 
 
2.2.1 DLS and DDLS 
Dynamic light scattering is a method to study the diffusion of macromolecules 
or assemblies in solution. It is based on the relation between the diffusion coefficient 
on one side, and the viscosity of the solution and the hydrodynamic radius of the 
objects on the other side. The setup consist in a laser, a detector and a correlator. It 
principle is illustrated in Figure 2-3: 
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Figure 2-3 : Principle of DLS and example of analysis. A) A laser is shone on the sample and 
the scattered light is collected by a detector at a defined angle θ (adapted from Claude Sauter). 
The signal is processed by a correlator to extract a characteristic time (t), which is related to the 
translational diffusion coefficient (DT) of the molecule. The hydrodynamic radius of the latter 
can be estimated using the Stockes-Einstein relation: rh=kT/6πµDT. B) Typical output of a DLS 
measurement for a monodisperse sample. The distribution of particle diameter in nm is plotted 
as a function of the percent of total intensity of scattered signal (on the X-axis).  
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The intensity of the scattered signal directly depends on the velocity 
(represented by the diffusion coefficient) of a particle in solution. Knowing this 
information, as well as the viscosity of the solution, enables an estimation of the 
hydrodynamic radius of the particles. In addition, DLS indicates whether the sample 
contains one (monomodal) or several populations (multimodal distribution, which is 
generally a sign of instability and aggregation) and whether these populations are 
homogeneous in size (monodisperse). Figure 2-3 (B) show an example of monomodal 
and monodisperse sample, which is a prerequisite for crystallization assays. 
 
DLS began in the early 90’s to be a method of choice to evaluate 
macromolecular interactions and detect formation of aggregates or assemblies in 
solution (Mikol et al. 1990). Thus, this technique was used as a diagnostic tool for the 
search of solvent conditions and crystallizing agents in which crystallization can occur, 
such as for lysozyme (Skouri et al. 1991) in the laboratory of Richard Giegé. However 
DLS later lost interest of the community for study of nucleation and crystal growth. It 
was rather used for sample quality control (characterization of the sample 
homogeneity) and for interaction studies thanks to its practical qualities: it is non-
invasive, non-destructive, provides fast, precise and reproducible quality check and 
requires only a minimum amount of sample (typically 2-20 µl; reviewed in Stetefeld et 
al., 2016). It was recently used again in crystallography analysis to study nucleation 
and crystal growth (Petsev and Vekilov 2000), in particular with its implementation in 
the Xtal Controller presented later in this thesis (Meyer et al. 2012; Schubert et al. 
2017; Baitan et al. 2018). Due to the increasing relevance of growing and 
characterizing micro- and nanocrystals for free electron laser (XFEL) studies, modified 
versions of DLS have also been developed. For example depolarized dynamic light 
scattering (DDLS) can distinguish nanocrystals from amorphous precipitate in a more 
reliable way (Schubert et al. 2015). This method is based on the differences in optical 
properties between ordered and disordered assemblies and allows to distinguish them 
but is still technically difficult.     
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2.2.2 TFL 
Detection by visual observation of crystals with white light in a crystallization 
assay is not always obvious. Crystals can be missed because they are hidden behind 
precipitate or by non-optimal placement in the droplet or close to the surface. In 
addition, distinction between salt and macromolecule crystals can lead to false positive 
and negative. A method to overcome these difficulties is the use of UV-illumination, but 
this is limited by the intrinsic fluorescence of tryptophan residues, the crystal packing 
as well as the materials used which need to be UV-transparent (Meyer et al. 2015). 
The TFL method introduced here leads to a much brighter fluorescent signal and is not 
limited by the protein sequence, folding or materials, as the excitation wavelength is in 
the visible spectrum (Pusey et al. 2008, 2015). It is based on covalently labeling on 
surface lysines of proteins with carboxyrhodamine-succinimidyl ester (Figure 2-4). 
 
 
Figure 2-4 : Chemical drawing of carboxyrhodamine-succinimidyl ester 
 
For this method, part of the protein solution is labeled in a one-step reaction and 
then mixed with the unlabeled stock solution. The use of a tiny percentage of labeled 
protein (less than 1% in total) is enough for bright detection (Figure 2-5) and was 
shown not to perturbate crystal growth nor diffraction (Pusey et al. 2015). The drops 
are illuminated with green light at 520 nm and observed after a low-pass filter at 550 
nm. 
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2.3 The Xtal Controller 
Recently a new instrument called Xtal Controller 900 was developed by the 
groups of Profs Christian Betzel (University of Hamburg) and Rolf Hilgenfeld 
(University of Lübeck) and the company Xtal-Concepts GmbH in Hamburg as a rational 
technology for the study and the preparation of biological molecule crystals (Garcia-
Caballero et al. 2011; Meyer et al. 2012). This instrument allows to manipulate a 
crystallization drop of a few µL by playing on the concentrations of macromolecule and 
crystallizing agent (thanks to microinjectors), while following the evolution of the 
system directly by DLS (detection of aggregation or nucleation events, formation of 
nanocrystals) and video-microscopy (monitoring of crystal growth), all in a 
temperature-controlled and humidity-controlled enclosure (Figure 2-6). 
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Figure 2-6 : Schematic representation of the Xtal-controller experimental chamber with all its 
technical parts (adapted from Baitan et al., 2018).  
 
The crystallization droplet is deposited on a coverslip, which sits on the ultra-
sensitive balance. This balance is the center of the instrument, allowing precise 
determination of concentration changes by measuring weight changes of the droplet. 
The use of microinjectors with reservoirs containing water and the crystallizing agent 
allows the experimenter to precisely control volumes and concentrations in the droplet. 
Measuring at the same time the evolution of assemblies by DLS and using a camera 
couple to a microscope enables to investigate the droplet during all stages of 
crystallization (Baitan et al. 2018). This instrument as well as its use will be described 
in more details later in this thesis. 
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3 Biological questions 
The biological part of this thesis was focused on enzymes involved in the 
maturation or aminoacylation of transfer ribonucleic acids (tRNAs) and of their 
complexes. Two aspects were studied: i) the structural characterization of a 
psychrophilic CCA adding-enzyme and ii) the biochemical characterization of inhibitors 
targeting aspartyl-tRNA synthetases, such as the one from the multi-resistant 
pathogen Pseudomonas aeruginosa.   
 
3.1 Transfer RNAs  
tRNAs are essential adaptor molecules present in every kingdom of life and are 
the most abundant non-coding RNAs in cells (reviewed in Kirchner & Ignatova, 2015). 
They are in charge of decoding the genetic information contained in the messenger 
RNA to translate it into peptides and proteins. Their structure is very characteristic and 
important for their function.  
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Figure 3-1 : 3D representation of tRNAAsp from Escherichia coli without CCA in conformation 
for binding to the aspartyl-tRNA synthetase. The different arms are colored individually: 
acceptor arm in orange, anticodon arm in blue, variable region in white, D arm in green and T 
arm in magenta (PDB entry 1EFW) (Briand et al. 2000).  
 
tRNAs exhibit a 2D cloverleaf structure, which fold into a characteristic L-shape 
in 3D (Figure 3-1). Their length varies between 73 and 96 nucleotides and five regions 
compose a tRNA. The acceptor stem, where aminoacylation will occur (orange), the 
anticodon hairpin (blue) which will decode the codon on the messenger RNA, a 
variable region (white) varying in length and the D (green) and T (magenta) arms.  
To fulfill their role, tRNAs are going through a long maturation process and are 
associated with a high diversity of partners. 
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Figure 3-2 : Structural gallery of tRNAs and their cellular partners (Fernández-Millán et al. 
2016).  
 
Figure 3-2 presents a gallery of tRNAs and partners with their respective 
structures, showing the diversity of existing interactions. Several key steps are 
represented, starting from tRNA maturation by the ribonucleic RNase P at the 5’-end 
(11), the ribonuclease Z at the 3’-end (12) and the CCA-adding enzyme for addition at 
the 3’-end (14), up to translation by the bacterial ribosome bound to EF-Tu:tRNA (10) 
(Schmeing et al. 2009; Reiter et al. 2010; Pellegrini et al. 2012; Tomita et al. 2004). In 
the middle are illustrated the aminoacylation of tRNAs by several enzymes, or even 
complexes, such as a monomeric glutaminyl-tRNA synthetase (4), a dimeric aspartyl-
tRNA synthetase (5) or the transamidosome (6) (Rould et al. 1989; Ruff et al. 1991; 
Blaise et al. 2010). 
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3.2 CCA-adding enzymes 
tRNA nucleotidyltransferases, among which can be found CCA-adding 
enzymes, include enzymes involved in the posttranscriptional maturation of tRNAs by 
polymerizing nucleotides at their 3' end. They belong to the polymerase β superfamily, 
which share the amino acid signature hG[GS]x(9,13)Dh[DE]h (x represents any amino 
acid, h represents a hydrophobic amino acid) (Holm and Sander 1995), and class II of 
this superfamily. Poly(A) polymerase, terminal uridylyl transferase, terminal 
deoxynucleotidyltransferase and tRNA nucleotidyltransferase form a subgroup inside 
the polymerase β superfamily which are able to add nucleotides at the end of DNA or 
RNA sequences without any nucleic acid template (reviewed in Betat et al., 2010). 
 
CCA-adding enzymes are tRNA nucleotidyltransferases able to add two 
cytosines and one adenine and maintaining this specific C-C-A sequence. The overall 
structure of class II CCA-adding enzymes exhibit a typical seahorse-like shape and is 
principally made of α-helices (Figure 3-3). The only beta sheet is in the head domain. 
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The enzyme can be divided into four domains: head, neck, body and tail; the catalytic 
center is located in a cleft formed by the head and neck domains, while body and tail 
domains recognize the tRNA. The motif A is the signature motif of all 
nucleotidyltransferases with two metal binding carboxylates DxD (x is any amino acid); 
Motif B is responsible for the discrimination between NTPs and dNTPs; Motifs C and 
E have no specific function assigned; Motif D is the single nucleotide-binding pocket 
specific for CTP and ATP (Tomita et al., 2004; Augustin et al., 2003; Li et al., 2002; 
Toh et al., 2009; reviewed in Betat et al., 2010).  
The polymerization activity of CCA-adding enzymes is performed without any 
DNA or RNA template, but is controlled by a set of highly conserved amino acid 
residues in addition to movements in the binding pocket (Tomita et al. 2006). A single 
CCA-adding enzyme must be able to adapt to all tRNAs in the cell, which requires a 
tightly controlled flexibility. Among others, the maturation of tRNAs by CCA-adding 
enzymes plays a key role in the faithful expression of the genetic code by its specificity 
and efficiency. This 3'-CCA sequence is necessary for further processing and roles of 
the tRNAs: (i) it is indeed the aminoacylation site for the aminoacyl-tRNA synthetases 
as the cognate amino acid is fused to the ribose moiety of the terminal A residue 
(Sprinzl, 1979), (ii) is required for positioning in the ribosome to ensure correct peptide-
bond formation during translation (Green and Noller, 1997), and (iii) is involved in 
translation termination when the nascent peptide is released from the ribosome 
(Simonovic and Steitz, 2008). During specificity switch between cytosine triphosphate 
(CTP) and adenosine triphosphate (ATP) during the polymerization process, not only 
amino acids near the catalytic center are subjected to movement, but also a global 
motion of the enzyme was observed (Tomita et al. 2006).  
 
3.3 Cold adaptation strategies 
Organisms living at low temperature needed to find adaptation strategies to still 
be able to perform enzymatic activities. Several strategies have been described and 
psychrophilic organisms usually combine them, meaning that cold adaptation does not 
rely on a single modification. Among others, an increased mobility of surface loops 
induced by the mutation of key residues (Åqvist 2017) and the destabilization of 
catalytic complexes to reduce their activation energy (Khrapunov et al. 2017) were 
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observed. In general proteins of psychrophilic origin display common features, 
enhancing their structural flexibility (reviewed in De Maayer et al., 2014). Intriguingly, 
the defined and controlled flexibility of CCA-adding enzymes does not seem to be 
compatible with an enhanced structural flexibility, associated with cold adaptation. This 
is why the structural study of the CCA-adding enzyme from Planococcus 
halocryophilus, a bacterium thriving in the Arctic permafrost (Mykytczuk et al. 2012) 
was initiated during this thesis. Cold adaptation is further developed in chapter III. 
 
3.4 Aminoacyl-tRNA synthetases 
Aminoacyl-tRNA synthetases (aaRSs) are essential enzymes that catalyze the 
covalent attachment of amino acids to their cognate tRNA. The aminoacylation 
reaction is a two-step process. The first step consists of the activation of the amino 
acid by an adenosine triphosphate with release of inorganic pyrophosphate (PPi), to 
form the aminoacyl-adenylate. This step occurs in presence of Mg2+ and is mostly 
tRNA independent, excepted for a limited set of aaRSs (ArgRs, GluRS, GlnRs; 
Schimmel & Söll, 1979). The second step corresponds to a nucleophilic attack by the 
2' or 3' hydroxyl of the ribose on the terminal adenylate in position 76 of tRNAs to form 
the aminoacyl-tRNA with the release of adenosine monophosphate (AMP) (Figure 3-
4).    
 
 
 
Synthetases are classified into two classes (class I and class II) and several 
subclasses (Figure 3-5) according to their structural organization.  
 
             
     
aa + ATP + aaRS aaRS●aa-AMP + PPi 
aaRS●aa-AMP + tRNA  aaRs + aa-tRNA + AMP 
Step 1 
Step 2 
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Figure 3-5 : Classification of aminoacyl-tRNA synthetases. The characteristic structural 
organization of each class is illustrated by the crystal structure of one member of the class in 
complex with its cognate tRNA, with the monomeric class I glutaminyl-tRNA synthetase 
(GlnRS) and the dimeric class II aspartyl-tRNA synthetase (AspRS). The table shows the 
partition of aaRSs in classes and subclasses (Eriani et al., 1990) and corresponding 
oligomerization states, as observed in bacteria (adapted from Claude Sauter). 
 
The classes possess very distinct structural and functional properties. Class I 
synthetases esterify the amino acid on the 2'-OH of the terminal adenosine of the tRNA, 
and bind the minor groove of the accepting arm. Their structure is organized around a 
domain consisting of a parallel beta sheet, surrounded by alpha helixes called 
Rossmann fold. They are essentially monomeric, with a few dimeric forms (α or α2). 
Class II aminoacyl-tRNA synthetases esterify the amino acid on the 3'-OH of the 
terminal adenosine of the tRNA, bind the major groove of its accepting arm and present 
a dimeric or tetrameric oligomerization state (Eriani et al. 1990) with a catalytic core 
build around an anti-parallel beta sheet.  
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3.5 Targeting synthetases from multi-resistant pathogens  
The 27th of February 2017, the World Health Organization (WHO) described 
antibiotic resistance of pathogens as one of the biggest threats to human health and 
called for a general effort of the scientific community in the discovery of new antibiotics 
(WHO, Tacconelli & Magrini, 2017). In accordance, they published a list of bacteria 
species or families for which new antibiotics are urgently needed, as they are 
developing resistance to known antibiotics, and classified them into three distinct 
categories of priority: critical / high / medium (Table 3-1) with new resistances recently 
observed. 
 
Table 3-1 : Published priority list by the World Health Organization 
Priority Bacteria Resistance 
Critical 
Pseudomonas aeruginosa  Carbapenem-resistant 
Acinetobacter baumannii Carbapenem-resistant 
Enterobacteriaceae Carbapenem-resistant 
High 
Enterococcus faecium Vancomycin-resistant 
Staphylococcus aureus 
Methicillin-resistant and 
vancomycin-intermediate resistant 
Helicobacter pylori Clarithromycin-resistant 
Campylobacter spp Fluoroquinolone-resistant 
Salmonellae Fluoroquinolone-resistant 
Neisseria gonorrhoeae 
Cephalosporin-resistant, 
fluoroquinolone-resistant 
Medium 
Streptococcus pneumoniae Penicillin-non-susceptible 
Haemophilus influenzae Ampicillin-resistant 
Shigella spp. Fluoroquinolone-resistant 
 
Among the “critical” category can be found the species Pseudomonas 
aeruginosa. This Gram-negative bacterium is an opportunistic pathogen, thus mostly 
affecting immunocompromised patients. It is responsible for hospital-acquired 
infections such as generalized inflammations and sepsis, which can be lethal when the 
colonization occurs in the lungs, kidneys or urinary tract.      
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Carbapenem, against which P. aeruginosa developed a resistance, are 
molecules in the family of the β-lactams, which are targeting penicillin binding proteins 
of Gram-positive and Gram-negative bacteria (reviewed in Papp-Wallace et al., 2011). 
They are unique in this family, as in some cases they are also inhibitors of β-
lactamases and are described as “last-line agents” or “antibiotics of last resort” in our 
antimicrobial armamentarium. The first carbapenem compound, thienamycin, used as 
model for subsequent developments, was discovered in 1976 and today, only around 
42 years later, resistance against this family is widespread (Table 3-1 and WHO 
reports).  
In the perspective of developing new active compounds, aaRSs are well 
recognized targets because these enzymes are essential to cell life. Chapter V will 
discuss the search of inhibitors targeting bacterial aspartyl-tRNA synthetases and drug 
design approaches. 
 
3.6 Serial crystallography at room-temperature 
At the beginning of bio-crystallography, a complete data set was collected on 
one or several large crystals (hundreds of μm in size) at room-temperature (RT). Later, 
due to the increase in synchrotron X-ray beam brilliance, cryo-cooling of crystals was 
developed to reduce radiation damages. These damages are inherent of the use of X-
rays, increase with the brilliance, induce a reduction of the diffraction properties of a 
crystal and accumulate in time (reviewed in Garman, 2010). Very recently in the field, 
thanks to the emergence of X-ray Free Electron Lasers (XFELs), a revival of room-
temperature and multi-crystal data collection is observed. These installations are very 
limited in term of numbers. As today, only five XFEL facilities are accessible around 
the world: LCLS in the USA, SACLA in Japan, European XFEL in Germany, PAL-XFEL 
in South Korea and SwissFEL in Switzerland. They allow the new approach called SFX 
for serial femtosecond crystallography which is based on the diffraction-before-
destruction principle and avoid radiation damage (Schlichting 2015). Due to limited 
number of XFEL installations, the collection system and strategy was recently adapted 
to synchrotrons and described as SMX for serial millisecond crystallography (Weinert 
et al. 2017) in opposition to SFX. In practice, a suspension containing nano- or 
microcrystals is produced and passed under X-ray radiation. Crystals hit by the XFEL 
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beam will produce one diffraction pattern before destruction. Therefore, collecting a 
complete dataset requires a high amount of crystals and diffraction patterns (reviewed 
in Johansson et al., 2017). This collection strategy pushed the development of new 
software to treat up to hundreds of thousands diffraction patterns produced by XFEL. 
Among others is ccCluster (Santoni et al. 2017) which was used in this thesis to 
analyze, compare and combine partial datasets collected in the microfluidic chips. The 
production and quality control of microcrystal suspensions for XFEL experiments is 
another challenge. One of the device developed to overcome it is the Xtal Controller, 
which is described in chapter IV. An additional advantage of the ultra-fast beam pulses 
is the development of what is called “molecular movies”. It consists in the collection of 
diffraction data corresponding to molecular snapshots along a reaction process. 
Thanks to the beam characteristics of XFELs and the mix-on-demand technology, 
fusion of these snapshot enables to study in more details protein dynamics and 
enzyme catalysis (Nango et al. 2016; Suga et al. 2017). 
 Serial RT analysis performed with XFEL or at synchrotron facilities is a new 
trend in crystallography. It enables studies without cryo-cooling and with no radiation 
damages in case of XFEL. 
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4 Thesis goal 
This thesis had two main aspects as indicated in its title “Application of new 
crystallization approaches and serial crystallography to the structural study of 
enzyme:tRNA complexes”, which where to i) carry out the structural and functional 
characterization of biologically relevant molecules and ii) develop and implement new 
crystallography methods. These tasks were performed simultaneously and associated 
to facilitate the structural studies performed during my PhD work.  
 
4.1 Biological target molecules 
Because of their essential nature and their substrate specificity, aaRS are prime 
targets for drug design. Part of this work has been the biochemical study and structural 
characterization of the binding mode of two families of AspRS inhibitors that specifically 
bind L-aspartate (see Chapter V). The first is represented by a natural antibiotic 
produced by some strains of E. coli to block the AspRS catalytic site of competing 
strains (collaboration with Professor Sylvie Rebuffat of the Musée National d'Histoire 
Naturelle, Paris); the second is a series of chemically synthesized peptides that were 
selected against the AspRS of the opportunistic human pathogen P. aeruginosa 
(collaboration with Professor Hiroaki Suga of the University of Tokyo). 
This work was also part of a French-German cooperation programme 
PROCOPE with the team of Professor Mario Mörl (University of Leipzig) on the 
structural study of CCA-adding enzymes of different organisms, including 
extremophiles. This cooperation led to the crystal structure of the enzyme Planococcus 
halocryophilus, a psychrophilic bacterium, capable of living at very low temperatures 
(see Chapter III). 
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4.2 New methods in crystallography 
The research team turned to an innovative and more rational technology for the 
preparation of biological molecule crystals called Xtal Controller 900 (Xtal-Concepts 
GmbH, Hamburg). This work explored the possibilities offered by this technology for 
the study of crystallogenesis and better control of crystal production for exploitation in 
structural biology (see Chapter IV). This led us to investigate the effect of different 
crystallizing agents on different protein models, but also of a new nucleant (mentioned 
in section 2.1.1), a lanthanide complex called Tb-Xo4 that facilitates the nucleation and 
growth of biological crystals (collaboration with Eric Girard from IBS, Grenoble). These 
experiments are based on proteins of biological interest, including a CCA-adding 
enzyme and proteins provided by our collaborators. 
The psychrophilic CCA-adding enzyme has also been used as a guinea pig for 
the development of crystallization methods and strategies, with the objective of further 
improving the quality of the structural data available. Following my participation in an 
international crystallization school2, two methods were introduced in the laboratory that 
have proven their effectiveness: trace fluorescent labelling (mentioned in section 2.2.2) 
that facilitates the identification of crystals during initial screening, as well as microseed 
matrix screening (mentioned in section 2.1.3) to increase the number of crystallization 
conditions. A new concept of microfluidic chips developed in the team was also used 
to determine the structure of several macromolecules at room temperature using the 
serial crystallography approach (see Chapter II)
                                                 
2 « Advanced methods in Macromolecular Crystallization VII » organized by the FEBS society in 2016 at Nové 
Hrady, Czech Republic. 
  
 
 
 
 
 
 
II. ChipX3: a new microfluidic 
crystallization device 
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En dépit de nombreux progrès en matière de criblage, l’exploration de 
combinaisons de solvants possible et du diagramme de phases pour identifier les 
conditions produisant des cristaux de qualité suffisante en diffraction, ceci à partir 
d’une quantité limitée de macromolecules reste longue et couteuse, et constitue un 
goulot d’étranglement des études cristallographiques. Ce processus implique 
généralement un échantillonnage par essai et erreur de l’espace chimique et physique 
en examinant des centaines de cocktails différents composés de tampons à différents 
pH, de divers agents de cristallisation et différentes températures pour trouver au 
moins un solvant approprié et des conditions de sursaturation propices à la croissance 
cristalline. La miniaturisation des essais de cristallisation dans des microplaques et 
l’automatisation de la procédure de criblage ont rendu cette tâche considérablement 
plus efficace, permettant de mener à bien un projet avec seulement quelques 
milligrammes d’échantillon pur. 
Dans ce premier chapitre de résultats de ma thèse, axé sur un développement 
méthodologique, le système de cristallisation en puce microfluidique est décrit avec 
tous les avantages qui vont avec (voir section 2.1.2), est décrit à travers deux articles 
en préparation. Premièrement en section 5 l’article « Crystallization and structural 
determination of an enzyme : substrate complex by serial crystallography in a user-
friendly and versatile microfluidic chip » préparé pour JoVE (Journal of Visualized 
Experiments) avec la vidéo associée, qui décrit le protocole de chargement d’une puce 
ChipX3 et la collecte in situ à température ambiante. Deuxièmement l’article « A simple 
and versatile microfluidic device for efficient biomacromolecule crystallization and 
structural analysis by serial crystallography » en section 6 qui présente une collection 
de cristaux obtenus dans les puces avec utilisation de méthodes avancées de 
cristallogenèse (voir section 2) et les stratégies d’analyse sous rayonnement 
synchrotron ainsi que les jeux de données et les structures associées. 
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5 Crystallization and structural determination of an 
enzyme:substrate complex by serial crystallography 
in a user-friendly and versatile microfluidic chip (in 
preparation for JoVE) 
 
Link to the video: 
https://seafile.unistra.fr/d/d9ecd3ed40674ffb9b37/ 
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6 A simple and versatile microfluidic device for 
efficient biomacromolecule crystallization and 
structural analysis by serial crystallography (in 
preparation for IUCrJ) 
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III. Structural and functional study of a 
psychrophilic CCA-adding enzyme  
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Dans ce second chapitre sont présentés deux articles qui concernent l’étude 
structurale et biochimique de l’ARNt nucléotidyltransférase de l’organisme 
Planococcus halocryophilus (PhaCCA), une bactérie vivant dans le permafrost 
arctique.  
Le premier article « Combining crystallogenesis methods to produce diffraction 
quality crystals of a psychrophilic tRNA-maturation enzyme » publié dans Acta 
crystallographica Section F décrit la stratégie de cristallogenèse employée pour définir 
rapidement et efficacement les conditions de croissance de cristaux de PhaCCA 
diffractant à haute résolution ouvrant la voie à la détermination de la structure de 
l’enzyme en question. 
La recherche des conditions de cristallisation d’une nouvelle biomolécule prend 
souvent beaucoup de temps et d’échantillons. Cette étape critique consiste 
généralement en l’examen de milliers de conditions de solvants. Cependant, il a été 
démontré que le fait d’élargir l’ensemble des essais de cristallisation au-delà de 
quelques centaines n’augmente pas de façon significative le nombre de conditions 
utiles. Au lieu de cela, l’utilisation d’approches alternatives qui fournissent un meilleur 
échantillonnage des conditions de sursaturation, facilitent directement la nucléation ou 
la détection des résultats positifs peut améliorer considérablement l’efficacité du 
processus de criblage (voir section 2). Dans ce travail axé sur les enzymes de 
maturation de l’ARNt, nous avons combiné le criblage conventionnel avec des 
méthodes de cristallogenèse plus avancées mais faciles à mettre en œuvre, pour 
accélérer la définition de conditions de cristallisation d’une nouvelle enzyme qui ajoute 
deux nucléotides cytosine et un nucléotide adénine à l’extrémité 3’ de l’ARNt, 
représentant le site universellement conservé d’aminoacylation des ARNt par les 
aminoacyl-ARNt transférases.  
Le second article encore en préparation est intitulé « CCA-addition in the cold : 
Structural and biochemical characterization of the enzyme from Planococcus 
halocryophilus » et se concentre sur les caractéristiques de l’adaptation au froid de 
l’enzyme PhaCCA. Celui-ci présente les résultats biologiques obtenus en partie grâce 
à l’utilisation de méthodes avancées de cristallisation employées lors de cette thèse. 
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  Plusieurs études comparatives entre les enzymes thermophiles et 
psychrophiles ont montré qu’il n’existait pas de stratégie universelle d’adaptation au 
froid. Au contraire, chaque enzyme semble utiliser des adaptations différentes. Dans 
la plupart des cas, ces adaptations aboutissent à une augmentation générale de la 
flexibilité de l’enzyme. Les CCA-adding enzymes sont des ARN polymérases 
hautement spécifiques qui ajoutent et maintiennent cette séquence en 3’ des ARNt. 
Pour une incorporation adéquate et efficace, des réaménagements structuraux sont 
nécessaires. Toutefois, pour les enzymes de cette famille qui sont adaptées au froid, 
il existe une contradiction entre une flexibilité étroitement contrôlée nécessaire à la 
spécificité de polymérisation et une flexibilité accrue en lien avec l’adaptation au froid. 
Des éléments de réponses seront apportés par la comparaison de l’enzyme 
psychrophile et de ses homologues thermophile/mésophile. 
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7 Combining crystallogenesis methods to produce 
diffraction quality crystals of a psychrophilic tRNA-
maturation enzyme (article in press in Acta Cryst. 
section F)  
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8 CCA addition in the cold: Structural and biochemical 
characterization of the enzyme from Planococcus 
halocryophilus (article in preparation) 
This section presents an article in preparation entitled: “CCA addition in the cold: 
Structural and biochemical characterization of the enzyme from Planococcus 
halocryophilus”. It provides the crystallographic characterization and biochemical 
analysis of the PhaCCA enzyme performed with our collaborators from the group of 
Prof. Mario Mörl in Leipzig.  
 
8.1 Introduction 
A variety of organisms are exposed to temperatures below 5°C and are 
described as psychrophilic. Because of their living conditions, their enzymes have to 
be cold adapted.  
 
8.1.1 Examples for adaptation strategies 
Several comparative studies between thermophilic and psychrophilic enzymes 
have shown that there is no universal strategy for cold-adaptation. Rather, each 
enzyme seems to use different adaptations to acquire enough flexibility to be active in 
cold environments. In most cases these adaptations lead to a reduction of non-
covalent stabilizing interactions, for instance via reduced hydrophobic cores, less 
charged surfaces, increased surface hydrophobicity, weaker interdomain interactions, 
less disulfide bridges, hydrogen bonds, or electrostatic interactions, increased number 
and size of loops and changes in amino acid composition leading to lower 
arginine/lysine ratio, lower amount of proline residues and higher frequency of glycine 
residues (Feller and Gerday 2003; Siddiqui et al. 2002; Siddiqui and Cavicchioli 2006; 
Struvay and Feller 2012; Yang et al. 2015; Sarmiento et al. 2015; Dick et al. 2016; 
Kovacic et al. 2016; Siddiqui et al. 2013). Recently, additional work on structural 
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strategies of cold adapted enzymes were published, showing that global 
conformational changes of the protein, rather than structural changes close to the 
active site, enhances the efficiency of substrate binding to the catalytic site, thus 
reducing activation energy and increasing substrate turnover rates (Hashim et al. 2018; 
Khrapunov et al. 2017; Lee et al. 2017; Sočan et al. 2018). 
 
8.1.2 Special case of RNA polymerases: need for controlled flexibility 
CCA-adding enzymes are highly specific RNA polymerases that add and 
maintain the sequence (C-C-A) at tRNA 3‘-ends (Sprinzl and Cramer 1979; Deutscher 
1990; Hoffmeier et al. 2010). These enzymes are not only vital in organisms that do 
not encode the CCA-triplet in their tRNA genes, but are equally important in organisms 
with encoded CCA ends for tRNA repair and quality control (Wellner et al. 2018). For 
proper and efficient CCA incorporation considerable structural rearrangements are 
required (Tomita et al. 2004; Ernst et al. 2015). However, for cold-adapted CCA-adding 
enzymes there is a discrepancy between the need of a tightly controlled flexibility 
during polymerization and an increased flexibility as a strategy for cold-adaptation.  
 
8.1.3 Recent work on psychrophilic CCA-adding enzymes  
In a recent study published by Ernst and coworkers in 2018 focused on 
Exiguobacterium sibiricum CCA-adding enzyme (EsiCCA), data from chimeric 
enzymes between psychrophilic EsiCCA and thermophilic enzyme from Geobacillus 
stearothermophilus revealed that both N- and C-terminal parts (corresponding to the 
catalytic core and the tRNA binding domain, respectively) are equally important for 
cold-adaptation. Whereas both parental enzymes exhibit the typical temperature 
dependent activities, both the chimeric enzymes are truly cold-adapted although they 
carry only a psychrophilic N- or C-terminal part. 
It was also shown that the CCA-adding enzyme from Planococcus halocrophilus 
(PhaCCA), a bacterium from the Arctic permafrost which grows at -15°C, is strongly 
cold-adapted and catalyzes CCA-addition down to 0°C in vitro (Ernst et al. 2018). 
Here, we provide a structural analysis of how this psychrophilic RNA 
polymerase (PhaCCA) is adapted to very low temperatures. 
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8.2 Results 
8.2.1 Functional analysis 
 
 
 
Figure 8-1 : Stability and fidelity from PhaCCA, BsuCCA and GstCCA, adapted from Ernst et 
al. 2018. A) In vitro activity assays at different temperatures. B) In vivo fidelity measurements. 
 
Figure 8-1 recapitulates the observations in Ernst et al, 2018. One can see in 
panel A results of activity assays performed at several temperatures with Pha, Bsu and 
GstCCA enzymes, which are psychrophilic, mesophilic and thermophilic respectively. 
PhaCCA is the only enzyme presenting more than 70% activity at 10°C and even 20% 
at 0°C, nicely illustrating its cold adaptation. On panel B, in vivo fidelity quantitative 
measurements were performed and significantly showed that PhaCCA is adding 
nucleotides to tRNAs with an increased error rate compared to the other ones. 
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8.2.2 Structural analysis of PhaCCA  
The PhaCCA enzyme was crystallized in its apo-form and soaked with CTP. 
Experimental phases were determined by sulfur SAD-phasing using a PRIgo 
goniometer (Waltersperger et al. 2015) and collected as described in Weinert et al., 
2015. Structural data and refinement statistics are presented in Table 8-1.  
Crystals were produced by combining advanced crystallogenesis methods as 
described previously (article in section 7, de Wijn et al., 2018), and led to X-ray analysis 
of crystals from the PhaCCA apo-form and in complex with CTP. Incorporation of CTP 
was performed by soaking the crystals 30 s in a drop containing the crystallization 
solution with 20% (m/v) glycerol as cryoprotectant and 5 mM CTP. Diffraction data 
were collected on crystals grown by vapor diffusion with microseeds in condition E8 
from JCSG++ commercial screen (Jena Bioscience) containing 100 mM sodium 
acetate, 1 M di-ammonium hydrogen phosphate, pH 4.5. SAD dataset was collected 
on beamline PXIII at the Swiss Light Source (Villigen, Switzerland).  
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Table 8-1 : Structural data and refinement statistics 
 PhaCCA SAD phasing PhaCCA Apo-form PhaCCA with CTP 
X-ray beamline SLS - PXIII SOLEIL – PROXIMA-1 SOLEIL – PROXIMA-1 
Wavelength (Å) 2.067 0.979 0.979 
Temperature (K) 100 100 100 
Detector Pilatus 2M-F Pilatus 6M Pilatus 6M 
Crystal-detector distance (mm) 120 320 296 
Oscillation (°  / s) 0.2 / 0.1 0.1 / 0.1 0.1 / 0.1 
No. of images 7 x 1800 1800 1677 
Space group P43212 P43212 P43212 
a, b, c (Å) 69.7, 69.7, 290.7 69.4, 69.4, 290.9 70.3, 70.3, 291.5 
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 
Mosaicity (°) 0.07 0.04 0.05 
Resolution range (Å) 50 – 2.25 (2.35 - 2.25) 50 – 1.8 (1.91 – 1.8) 50 – 1.85 (1.96 – 1.85) 
Total No. of reflections 5015162 (223140) 890444 (139573) 776857 (123819) 
No. of unique reflections 64194 (7615) 68555 (10787) 63935 (10060) 
Completeness (%) 99.0 (96.3) 99.9 (99.3) 99.8 (99.2) 
Redundancy 78.1 (29.3) 13.0 (12.9) 12.2 (12.3) 
〈I/σ(I)〉 30.8 (1.11) 19.5 (0.66) 22.11 (0.95) 
Rmeas (%) 17.0 (278.4) 7.4 (264.8) 6.9 (239.4) 
CC1/2 (%) 99.9 (51.8) 100 (59) 100 (45.1) 
Overall B factor from Wilson plot (Å 2) 36.2 44.8 45.0 
No. of reflections, working set / test set 34091 / 1813 64991 / 3420 60676 / 3195 
Final Rcryst (%) / Rfree (%) 22.8 / 27.0 24.4 / 26.7 19.8 / 22.4 
No. of non-H atoms 2967 2989 3422 
R.m.s. deviations     
 Bonds (Å) 0.009 0.008 0.008 
 Angles (°) 1.07 1.01 1.07 
Average B factors (Å2)  43.7 41.6 40.9 
 Protein 43.7 41.6 40.1 
 Water / / 47.6 
Ramachandran plot     
 Most favoured (%) 97.0 99.0 98.0 
 Allowed (%) 2.7 0.7 1.7 
Rotamer outliers (%) 0.9 0.6 0.6 
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Figure 8-2 : Overall structure of PhaCCA. A) Cartoon representation of the enzyme with the 
typical seahorse-like shape with bound CTP substrate. Domains are represented in different 
colors: blue for head, green for neck, yellow for body and orange for tail. B) Electron density 
map of the catalytic site with CTP. C) Electron density map from the sulfur SAD-phasing. Maps 
are contoured at 1.2 sigma. 
 
The PhaCCA crystal structure was determined by sulfur SAD phasing. A 
snapshot of the experimental map at 2.1 Å is presented panel C. The complex with 
CTP was obtained at 1.85 Å resolution and is presented in mode cartoon Figure 8-2 
panel A. The electron density map of the CTP is well defined (panel B).  
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To determine variations in the helix content of different structures (our apo-form 
and a selection of other structures from the PDB) we used the web-server DSSP (Touw 
et al. 2015). It uses pdb files to determine their content in secondary structure elements 
as summarized in Table 8-2. Percentages indicated in this table were normalized to 
the number of amino acids in the protein or in the indicated domain, without taking 
purification tags into account. If we only consider the whole enzyme, only marginal 
differences can be observed between Pha and GstCCA. But taking a closer look at the 
body domains, which are less conserved and thus more susceptible to exhibit 
adaptations, a reduction of 5% in the helices content is observed in PhaCCA with 
respects to other enzymes.  
Table 8-2 : Alpha-helix contents in CCA-adding enzyme structures from different bacteria. 
Calculations of percentages were performed using the DSSP web-server. 
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Figure 8-3 : Comparison of Pha (red) and GstCCA (blue) enzyme structures. A) Structural 
alignment and B) close-up view of a region of the body domain, highlighting significant 
secondary structure differences. 
 
Pha and Gst enzymes can be superimposed with an RMSD of 1.4 Å (calculated 
with PYMOL, Figure 8-3 panel A). Head and neck domains exhibit very few 
differences, whereas a loss of α-helices in the body domain of the PhaCCA can be 
observed (as presented in Table 8.2). One instance is illustrated in panel B from amino 
acids 227 to 237, highlighted in blue. This reduced content of α-helices is a hallmark 
of psychrophilic enzymes (as mentioned above). This kind of adaptation may arise in 
this C-terminal domain which is generally less conserved and thus more tolerant to 
variations, in contrast to the N-terminus which is highly conserved because it is 
involved in catalysis. 
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8.3 Discussion   
Several studies showed that psychrophilic adaptation can be reached without 
any amino acid substitution in the active site (Struvay and Feller 2012). Very often, a 
cumulative effect of different changes outside the catalytic core leads to cold-
adaptation and even single substitutions of individual residues can have long-range 
effects on the general stability of the enzyme (Fitter 2005; Siddiqui and Cavicchioli 
2006; Struvay and Feller 2012; Kovacic et al. 2016). For example, in adenylate kinase, 
a single methionine replacement (from the thermophilic homolog) to threonine (in the 
cold-adapted homolog) is sufficient to generate the required flexibility of the 
psychrophilic enzyme (Bae and Phillips 2004). In addition, in comparative studies of α-
amylases of different Bacillales it was shown that an exchange of individual residues 
can increase or decrease the enzyme’s overall thermostability (Fitter 2005). 
A number of studies have raised the question whether cold-adapted proteins 
achieve flexibility throughout their whole structure (global flexibility) or whether they 
have distinct regions of local flexibility (Siddiqui and Cavicchioli 2006). The cold-
adapted Pha CCA-adding enzymes uses a global flexibility in the tRNA-binding C-
terminus, indicated by a reduction of α-helix content.  
It was already shown for cold-adapted CCA-adding enzymes from Planococcus 
halocryophilus and Exiguobacterium sibiricum that their adaptation comes with a 
tradeoff in activity, stability and fidelity (Ernst et al. 2018), but as presented here this 
adaptation is not occurring in the nucleotide binding pocket. As it occurs in tRNA-
binding C-terminus, it could be related to mistakes in tRNA binding.  
8.4 Conclusion 
The remarkable cold adaptation of PhaCCA seems to be linked to an increased 
overall flexibility and a lower thermal stability of the enzyme provided by the loss of 
secondary structure elements. Hence compared to the thermophilic CCA-adding 
enzyme from Geobacillus stearothermophilus, the structure of the PhaCCA enzyme 
shows a reduced content of alpha-helices in its body domain. 
However, the price to be paid for such a cold-adaptation of PhaCCA is not only 
a thermal destabilization, but, importantly, a significant reduction in polymerization 
fidelity. 
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IV. Crystallization study with the Xtal 
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Ce troisième chapitre a pour but de présenter l’instrument Xtal Controller ainsi 
qu’une sélection d’expériences qu’il a permis de réaliser. Ces travaux s’inscrivent dans 
le développement de nouvelles approches de cristallogenèse appliquées à des 
systèmes protéiques présentant un intérêt biologique pour le laboratoire. 
En dépit des progrès récents sur les techniques de croissance cristalline, la 
recherche de cristaux ou encore les méthodes de diagnostic, la détermination de 
conditions de cristallisation et leur optimisation reste très empirique. Les méthodes 
classiques ne permettent pas un contrôle direct de la nucléation ni de la croissance. 
Le concept du Xtal Controller 900 (XC900) a pour objectif de combler ce manque. 
Comme présenté en section 2.3, cet instrument permet un contrôle précis des 
paramètres physico-chimiques autour et à l’intérieur d’une goutte de cristallisation : 
température, humidité, concentrations des macromolécules et de l’agent cristallisant. 
La modification des concentrations est rendue possible par la présence de deux 
pompes reliées à un réservoir contenant soit de l’eau, soit l’agent cristallisant. Le 
XC900 rend également possible le suivi en temps réel de l’évolution de la goutte par 
l’utilisation d’une caméra couplée à un microscope, ainsi que d’un appareil de DLS. 
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9 Introduction to the Xtal Controller system 
Despite recent advances in crystal growth, crystal detection and diagnostic 
methods (DLS), research and optimization of crystallization conditions remains 
empirical. We do not control nucleation or growth in the classical methods (sections 1 
and 2). 
Experiments in microgravity in space started in the late 80’s (Vergara et al. 2005) 
helped the development and rationalization of crystallization practices but the 
community was still lacking an instrument that brings a complete control and follow-up 
of a crystallization experiment. It was in this context that the concept that led to the Xtal 
Controller germinated (Garcia-Caballero et al. 2011). The instrument provides the 
follow-up by DLS and camera and a means of action by the piezo-pumps. It was built 
in the lab of Prof. Christian Betzel (University of Hamburg) then developed and 
marketed by Xtal Concept. Our team is the first lab to have acquired this technology at 
the beginning of my thesis, which allowed me to use it and establish experimental 
protocols. 
This instrument was initially conceived for a purpose of crystal growth in difficult 
cases: when no usable crystals where available or in case of sensitive systems (which 
were either remaining clear or precipitating) with aim to control and slow down the 
system. New applications were also more recently envisaged: development of protocol 
for preparation of nanocrystals suitable for XFEL analysis with use of the DLS or more 
recently, the study of nucleating agent addition to determine the effect on kinetics of 
nucleation and growth. 
Figure 9-1 presents some important features of the instrument and pictures. A 
more detailed schematic representation is given section 2.3. 
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Figure 9-1 : Pictures of the Xtal Controller in our laboratory with view of the experimental 
chamber. Some important elements are indicated on the right with their localization. 
As described before, this instrument allows a precise control of several 
conditions inside a crystallization droplet: temperature, humidity, macromolecule and 
crystallization agent concentrations. It enables to follow a desired path inside the phase 
diagram (Figure 9-2). Movements are made possible thanks to the controlled use of 
the different pumps and of evaporation. 
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Two articles were recently published involving the use of the Xtal Controller 
(Schubert et al. 2017; Baitan et al. 2018). Schubert et al, 2017 describes some 
observations by electron microscopy of populations detected by DLS in the instrument 
for model proteins. The second one published in JoVE presents an experimental 
protocol to grow crystals in the instrument. No publication is available yet on 
applications that do not concern model proteins or standard experiment. 
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10 Setting up an experiment 
The following protocol for the Xtal Controller 900 was written in collaboration with 
Daniela Baitan PhD candidate in the Xtal Concepts startup and in the group of Prof. 
Christian Betzel. The same steps were followed for all experiments, except when 
mentioned. The graphical user interface (GUI) is split in three windows (Figure 10-1): 
the camera window on the right, the curve panel at the bottom and the main control 
window with all experimental subdirectories accessible on the left. 
 
 
Figure 10-1 : Screenshot of the complete Xtal Controller GUI. 
  
10.1 Launching the software 
- in a Terminal console go to the pms directory (cd /pms) 
- start the program (python main.py). This will automatically launch the software and 
the connection to the instrument. 
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10.2 Creating a new project 
- Go to LIMS panel (Figure 10-2) 
 
 
Figure 10-2 : Screenshot of the “LIMS” panel. 
- Right click on the user folder / Add / Project name and Project description 
- Right click on the project that has just been created and create new experiment. This 
will create a new folder which will further contain the desired tests for your sample. 
- Right click on the experiment folder / Add / Plate name to enter a new drop experiment 
and give it a name. Also a short description of the conditions and of the sample can be 
added in “Plate description”. Follow the window protocol for your experiment. Only 
letters should be used for the description of the protein/precipitant or other substances 
and only numbers (e.g. 10 or 10.5) for concentrations. 
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Press the green box with the two arrows to start your experiment. You will be asked to 
introduce your experiment. Click on the new created experiment and validate by 
clicking “Insert”. 
 
IMPORTANT: directly start a first DLS measurement to set t=0 for DLS. 
 
10.3 Experimental Setup 
 
10.3.1 Temperature and humidity 
 
- Go to “Parameter” (Figure 10-3) and set up the temperature in the “Temperature (C)” 
and the humidity in the “Dewpoint (C)”. Note that the Dewpoint value cannot exceed 
the temperature value. Two equal values will mean 100% humidity in the chamber. 
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Figure 10-3 : Screenshot of “Parameter” panel. 
- Open the lid and the door of the experimental chamber 
- Load the cover slip by using the pallet/ passe partout (the passe partout is at the right 
position when you feel a smooth click) 
 
10.3.2 Pumps and protein drop  
 
- Go to “PUMP” (Figure 10-4) to define the initial setup. 
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Figure 10-4 : Screenshot of the “Pump” panel. 
- Piezo Pump 0 injects water and Piezo Pump 1 the precipitant (crystallant) solution. 
When using high viscosity solutions, first set the nozzle heating power to the desired 
percentage. No detailed viscosity assays were performed to determine the upper limit 
but as an example 5 % (m/v) is close to the concentration limit manageable by the 
pump for PEG 3350. 
- Test each pump individually. Click “OK” for a few drops or “On” for a continuous jet 
shooting. 
- Align manually the two pumps in such a way that they shoot at the same position on 
the cover slip. This can be done by using the two screws (blue for water, grey for 
precipitant) on the right-hand side of the instrument. 
- After alignment, the cover slip can be exchanged with a clean one for setting up the 
protein drop. 
Chapter IV Crystallization study with the Xtal Controller 
 
125 
 
- After the new cover slip has been placed in, press “TARA”. Then, press “OK” or “On” 
for the water pump. This will generate a drop indicating the position to deposit the 
protein drop. 
- After depositing the protein drop close the lid and the door. 
- Press on “Const” (to ensure constant weight by injecting water to compensate for 
drop evaporation) and then on “New drop” (to declare the record of a new experiment). 
- Check in the top-left white window that the values are correct and the precipitant 
molarity “mol” of the drop is set to zero. From this time on, the protein is setup in a 
constant mode where the drop weight is kept constant. 
 
10.3.3 Experimental schedule 
 
In the schedule table, precipitant addition, evaporation/concentration of the droplet as 
well as a constant weight mode for the droplet can be planned. 
Table description: 
 
“Liquid” column 
- For water write “water” 
- For precipitant write “prec” 
 
“Slope/molar.” column 
- For water addition (dilution/constant mode) the value introduced represents the 
percentage of drop weight that will be added/evaporated. 
E.g.: “water 0.4” indicates that water will be added to extend the drop weight by 40% 
whereas “water -0.4” that the drop will be evaporated until the weight is down by 40%. 
- For precipitant addition, the value introduced represents the precipitant molarity which 
will be added to the sample drop. The value introduced cannot exceed the initial 
concentration of precipitant. 
 
“Time (s)” column 
- Enter the time planned for each step in seconds. 
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NB: At the beginning of each experimental schedule, set a line for the automatic 
adjustment of the weight in a constant mode. This should be: 
water    0.0    100 
 
To start the experimental schedule, press “Autom.”  
 
10.3.4 DLS measurements 
 
When the drop is ready, check the position of the DLS laser in the droplet. It should 
not be too close to the drop limit (where the light path through the mother liquor is 
minimal). 
- Go to the camera window (Figure 10-5) 
 
Figure 10-5 : Screenshot of the camera panel. 
- Make sure the “illumination/white light” is switched on. 
- Activate the laser by clicking “Laser on”. 
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- The laser position can be adjusted manually by using the two screws on the left-hand 
side of the device. They will coordinate the laser X and Y position. 
- To check the DLS position, go to “DLS” (Figure 10-6) and press “START”. This will 
run a first DLS measurement. If the auto-correlation function and/or the Count rate do 
not have a good signal, readjust the laser position. If the signal is not good enough, 
press “STOP” before the measurement ends. This will prevent it from being recorded. 
(In this case, each measurement takes 60 seconds). 
 
Figure 10-6 : Screenshot of the “DLS” window of a test experiment. 
 
10.3.5 To setup a series of DLS measurements and/or of images  
 
- Go to Autopilot (Figure 10-7) 
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Figure 10-7 : Screenshot of the “Autopilot” window 
-In the “Action” box, choose the type of action you want to schedule (DLS/Image/Calib). 
*The “Calib” action is not intended to be scheduled on a regular basis. This should only 
be used at times, when the balance is showing a drifting or when strange jumps occur 
in the curves.  
- After selecting the action, fill in the next boxes. 
“Start time (min)” - this represents the time when the action starts. “0” means that the 
action will start as soon as one presses “Add to schedule”. 
“Waiting time (min)” - is the time period between two actions. 
“Number of scans” - is the total number of action planned during the experiment. 
 
To activate the schedule, press “Add to schedule”. This will also show you a summary 
of the number of scans and the time period for it. 
To check the schedule, go to LIMS panel and click on the second icon from the top 
“Schedule”. 
Chapter IV Crystallization study with the Xtal Controller 
 
129 
 
To remove the schedule actions press right click on the table and continue.  
 
To check the status of the experiment, check the DLS measurements or the images 
that are being recorded. This is done in “LIMS” with a single click on the experiment 
file. At the bottom of the window, there are buttons to access DLS measurements and 
Plate Images. 
 
10.4 Stopping an experiment 
 
When an experiment is finished and the cover slip has to be removed, make sure at 
first that the “experimental schedule” in “PUMP” is stopped by pressing the “Stop” 
button. Then the cover slip can be removed. 
In the case where DLS measurements images are still scheduled after the experiment 
finished, go to the “Schedule” and remove all remaining entries. 
 
During the experiment, results of measurements can be monitored live following the 
parameter curves (including concentrations extrapolated from the weight record), as 
well as DLS heat map and size distribution plot indicating the evolution of particle 
populations in the drop (Figure 10-8). 
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Figure 10-8 : Monitoring drop evolution through parameter curves (top), particle radius plot 
(bottom left) and heat map (bottom right). Curves are presented with different colors: red for 
the weight, blue for the protein concentration, green for precipitant (crystallant) solution and 
black for the temperature. X and Y-axes of the radius plot represents the time (in s) and the 
radius (in nm), respectively. Sizes of the dots are proportional to the scattering signal intensity. 
In the heat map, the axes are exchanged: X-axis corresponds to the radius and Y-axis to the 
time. Intensities of measurements are illustrated by colors from blue to red. 
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11 Results 
Different types of experiments were performed with the Xtal Controller on various 
protein targets. A selection is presented in this chapter, illustrating what can be 
performed with the instrument. 
 
11.1 Presentation of a precipitation case 
Before interpreting crystallization events with the help of the DLS, a precipitation 
case with it characteristic pattern is presented (Figure 11-1). In this case, precipitation 
was induced on purpose by a rapid and concomitant increase of the PhaCCA enzyme 
and crystallizing agent (100 mM sodium acetate, 1 M di-ammonium hydrogen 
phosphate, pH 4.5, as described in chapter III) concentrations. Precipitation is 
characterized in the DLS profile by a burst in the particle size (radius) and the complete 
disappearance of the monomeric fraction with a radius size below 10 nm. Accordingly, 
a strong dark precipitate can be observed with the camera (right picture). 
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11.2 Crystallization of the CCA-adding enzyme from P. 
halocryophilus 
A controlled crystallization protocol of the PhaCCA enzyme was established in 
the Xtal Controller, followed by crystals analysis at the ESRF. The same crystallizing 
agent as presented in section 11.1 was used and the protein was at 5 mg/mL at the 
beginning of the experiment. A complete experimental procedure with results is 
illustrated in Figure 11-2 from schedule, curve profiles, DLS plots, drop pictures, to 
diffraction patterns and resulting electron density map.  
The DLS profile is very different compared to the one in the precipitation case: 
the monomeric fraction remains present and a population between 1000 and 2000 nm 
appears and remains stable. According to its size, this population corresponds to 
micro- or nano-crystals. To define them more precisely, an electron microscopy 
analysis of this population should be performed. Interestingly, this population is 
observed by DLS immediately after the start of crystallizing agent injection, but crystals 
become visible at the edge of the droplet after more than 24 hours and further addition 
of crystallizing agent. After completing the Xtal Controller experiment, the coverslip 
was transferred to a Limbro plate over a reservoir containing the same salt 
concentrations as the droplet to maintain it on an equilibrium. After five months only a 
slight increase in the crystals size was observed. One of these crystals was prepared 
for diffraction and cryocooled at 100 K as presented in chapter III. Diffraction at the 
ESRF (Grenoble) on beamline BM30A allowed collection of a complete dataset at 1.85 
Å (illustrated in the bottom panel).    
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11.3 Tracking of the effect of Tb-Xo4 on nucleation and crystal 
growth 
I used the instrument to test the effect of Tb-Xo4 nucleant provided by our 
collaborators (Eric Girard and Sylvain Engilberge, CEA Grenoble) on nucleation and 
crystal growth. In this section, a selection of experiments carried out on several target 
proteins are presented.  
11.3.1 Hen egg white lysozyme in water 
Our collaborators published a study showing a spectacular effect of Tb-Xo4 on the 
phase diagram of commercial hen egg white lysozyme crystallized in the presence of 
NaCl (Engilberge et al., 2017). In addition, they also observed that lysozyme can be 
crystallized in water containing 10 mM Tb-Xo4 without any other salt (unpublished 
results). In this context, we decided to follow the effect of the addition of Tb-Xo4 to 
lysozyme only solubilized in water. For this, we developed a specific experimental 
protocol. It consists in a manual addition of 1 µL of 100 mM Tb-Xo4 to a 10 µL lysozyme 
droplet (by the means of an Hamilton syringe) to a final concentration of 10 mM of 
nucleating agent, while the Xtal Controller is running in constant mode. This mode 
implies that the instrument will keep the weight stable to a beforehand defined value 
by shooting water to compensate for evaporation. The addition of 1 µL to the droplet 
induces a punctual and sharp weight increase. The instrument will then stop shooting 
water until evaporation brings the weight back to the target value. Tb-Xo4 was added 
after an incubation time was introduced in the protocol to check the stability of 
lysozyme in water. To assess if manual addition of solution was not disturbing the 
solution and inducing some pattern in the droplets, we performed a control experiment 
by adding 1 µL water. An experiment and the corresponding control following this 
protocol are presented Figure 11-3.   
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Figure 11-3 : Monitoring Tb-Xo4 addition to a lysozyme solution in water and corresponding 
control experiment with water addition. Top panels present the DLS profiles, green bars 
indicating manual addition of Tb-Xo4 or water. Bottom panels present pictures from the droplet 
taken at the beginning and the end of the experiment.  
 
Experiments were performed with lysozyme in water at 20 mg/mL and no 
crystallizing agent. Addition of Tb-Xo4 to the droplet is easily observable on the weight 
curve as well as the time needed for the system to come back to its initial weight. In 
the DLS profile, addition of Tb-Xo4 is also clearly visible as it is characterized by two 
responses: increase of the monomeric population size (such as in Schubert et al., 
2017) and appearance of particles with a size about 1000 nm. These effects are not 
induced in the control (top right panel). Interestingly, these particles are not yet visible 
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with the camera, the droplet remains clear even at the end of the experiment (bottom 
panels). 
 This study clearly presents a direct nucleation effect of the crystallophore Tb-
Xo4 addition on lysozyme in water, without added buffer and crystallizing agent. To 
conclude this study, droplets should be analyzed before and after addition of Tb-Xo4 
by electron microscopy to confirm the formation of nanocrystals.   
 
11.3.2 Protease 1 
A second protein model, protease 1 from Pyrococcus horikhoshii, was used to 
study the effect of Tb-Xo4 with the Xtal Controller. Our collaborators were able to 
crystallize this protein in 2.9 to 3.2 sodium malonate at pH 5 in the absence or presence 
of Tb-Xo4 (Engilberge et al., 2017 and unpublished results). For this model, the same 
experimental protocol as described in section 11.3.1 was applied, with addition of 3.4 
M sodium malonate pH 5 as crystallizing agent after an incubation period, as addition 
of Tb-Xo4 alone was not inducing a visible effect. Protease 1 was used at 7.6 mg/mL 
in Tris-HCl pH 8. A control experiment with water is presented Figure 11-4, and that 
with Tb-Xo4 Figure 11-5. 
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The reaction of protease 1 to the addition of Tb-Xo4 seems different compared to 
lysozyme. No direct and strong effect was observed immediately after its addition, but 
a secondary addition of crystallizing agent was necessary after an incubation time, to 
detect the influence of the nucleant. In the control experiment without Tb-Xo4 with 
water addition, a precipitation like effect (as described in section 11.1) is observed just 
after addition of the crystallizing agent and the droplet was precipitated at the end of 
the experiment. This is probably due to a destabilization of the protein by too rapid 
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addition of sodium malonate. In the presence of Tb-Xo4, the behavior is different. As 
described in section 11.2, the monomeric fraction increased in size and a stable 
population around 1000 nm appeared. This led to crystals as illustrated in the bottom 
panel of Figure 11-5.   
In the case of protease 1, addition of Tb-Xo4 seems to stabilize a defined population 
after addition of sodium malonate and avoids a disordered association leading to 
precipitation, but does not present a direct effect after addition. As for the lysozyme 
study, the visualization of the particles with electron microscopy could be relevant to 
characterize their nature. Further experiments could be performed:  
1. Use the protein at a lower concentration to accentuate the difference between 
situations with and without Tb-Xo4.  
2. In the opposite direction, increase protein concentration to test if there is a 
threshold beyond which a direct effect of Tb-Xo4 can be observed.  
3. Our collaborators identified several binding sites of Tb-Xo4 on protease 1 and 
designed mutants of interacting residues (unpublished results), which could be 
interesting to confirm the effect of Tb-Xo4.  
4. This system seems very sensible to crystallizing agent addition, so it is an 
interesting model for kinetic experiments, where sodium malonate could be 
added very slowly to the droplet to detect a potential induction threshold. 
 
In conclusion, this series of experiments allowed us to get insights into early 
nucleation and growth events for different systems. It illustrates the power of using in 
situ DLS for monitoring in real time the evolution of particle populations in a 
crystallization drop. In addition, it was extremely useful to finalize the implementation 
of the technology in the laboratory, test the possibilities offered by the Xtal Controller 
and develop new protocols.  
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Ce dernier chapitre est axé sur l’étude de deux familles d’inhibiteurs de l’AspRS. 
La communauté scientifique a constamment besoin d’innovation dans le 
développement d’antibiotiques pour faire face à l’apparition rapide de résistances 
bactériennes par évolution et transfert horizontal de gènes, tel que présenté à la 
section 3.5. Dans ce contexte, les méthodes de conception de nouvelles molécules 
présentent une importance stratégique de santé publique. Les aaRS étant des 
enzymes essentielles, l’inhibition de l’une d’entre elles entraine l’arrêt de la synthèse 
des protéines, ce qui a un effet létal. Ces enzymes sont donc des cibles intéressantes 
pour le développement d’antibiotiques dans la lutte contre les bactéries et autres 
microorganismes. 
La première famille est composée de peptides macrocycliques contenant des 
acides aminés non conventionnels. Le design de ces peptides repose sur le système 
RaPID (Random nonstandard Peptide Integrated Discovery). Six peptides ont été 
sélectionné par cette procédure dans le but de tester leur effet inhibiteur ainsi que leur 
potentiel pouvoir d’agent co-cristallisant de l’AspRS de Pseudomonas aeruginosa. La 
seconde famille est un inhibiteur naturel, la microcine C, un analogue de l’intermédiaire 
réactionnel naturel qu’est l’aspartyl adenylate, découvert dans la famille des 
Enterobacteriaceae et qui empêche la croissance d’organismes concurrents. 
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12 Macrocyclic peptides against the AspRS from 
Pseudomonas aeruginosa 
12.1 Introduction to the RaPID system  
The scientific community is in constant need of innovation to combat bacterial 
resistance development through evolution and gene transfer, as presented in section 
3.5. In this context, methods for design of new molecules, drugs, are gaining 
importance. Inhibition of aaRSs causes protein synthesis to stop, which has a lethal 
effect. These enzymes are therefore attracting targets for antibiotics development in 
the fight against bacteria and other microorganisms. 
One method to find new active molecules is the Random non-standard Peptide 
Integrated Discovery (RaPID) developed by the team of Prof. Hiroaki Suga in Tokyo, 
Japan (Figure 12-1, reviewed recently by Passioura & Suga, 2017). The aim of this 
process is to find, within partially randomized libraries, macrocyclic peptides containing 
unconventional amino acids that are able to specifically bind a target. These peptides 
are then tested for their potential inhibition capacities on the same target.    
The central element of this procedure is the Flexible in vitro Translation (FIT) 
system and genetic code reprogramming (Goto et al. 2011). This translation system is 
based on the fact that the genetic code not only relies on the specificity 
codon:anticodon carried out by the mRNA:tRNA recognition, but also on the specific 
aminoacylation of tRNAs with their cognate amino acid by the corresponding 
aminoacyl-tRNA synthetase. Thus, one can reprogram the genetic code without 
interfering with the codon:anticodon recognition by changing the amino acid carried by 
tRNAs. This presents the advantage, over modification of the codon:anticodon 
recognition, that the reprogramming is not limited to STOP or rare codons. This was 
made easier in 2001 by the invention of a first ribozyme prototype, called flexizyme 
(Fx), able to aminoacylate tRNAs (Saito and Suga 2001). Hiroaki Suga and his team 
later enhanced the system and developed a set of three flexizymes, called dFx, eFx 
and aFx virtually able to perform aminoacylation with any unconventional amino acid 
(Murakami et al. 2006; Niwa et al. 2009). The FIT is a reconstituted bacterial translation 
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system containing all factors necessary for translation including all aminoacyl-tRNA 
synthetases, excepted the one associated to the reprogramed tRNA. This specific 
tRNA will be associated to a flexizyme for aminoacylation. 
 
   
As illustrated in Figure 12-1, the first step of the RaPID selection process 
consists in the transcription of a partially randomized mRNA library and attachment of 
a puromycin linker to their 3’-end. These mRNA are then transcribed in a FIT system 
(allowing incorporation of unconventional amino acids) and peptides are cyclized (step 
2). The puromycin linker allows the mRNA to be covalently attached to the peptide 
chain and causes the end of synthesis by the ribosome. Following comes a reverse 
transcription (step 3) and the affinity selection of peptides against immobilized targets 
(step 4). Finally the DNA sequence of the selected peptides are recovered by PCR 
amplification (step 5). This cycle is repeated several times until specificity is reached 
and enough enrichment is obtained to sequence the DNA. Macrocyclic peptides were 
chosen as potential drugs because they present several advantages. They have the 
potential to combine characteristics of small molecules (rapid degradation in the 
organism and relatively easy synthesis) and of bigger biomolecules, as antibodies and 
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hormones (specificity and interactions with macromolecules). Example of success 
stories of the use of the RaPID system concern the inhibitors of the Akt2 human kinase 
(Hayashi et al. 2012) or the inhibitors and cocrystallization ligands of a MATE family 
transporter (Hipolito et al. 2013; Tanaka et al. 2013). We decided to apply the RaPID 
selection to find binders and potential inhibitors of the aspartyl-tRNA synthetase 
(AspRS) of P. aeruginosa, a pathogen rapidly developing resistances. 
 
12.2 Macrocyclic peptides 
 
P. aeruginosa possesses just one non-discriminating aspartyl-tRNA synthetase, 
able to aminoacylate tRNAAsp and tRNAAsn (Bernard et al. 2006). The latter is loaded 
with L-Asp which is then converted in L-Asn by an amidotransferase to compensate 
for the absence of AsnRS in the bacterium. 
The protein batch used to perform RaPID selection was purified by the team of 
Prof. Jacques Lapointe in Québec (Canada). The selection process was performed 
during my internship in the lab of Hiroaki Suga (Tokyo, Japan) in summer 2014, under 
the supervision of Toby Passioura. Toby finalized the last selection round, purified the 
peptides, performed surface plasmon resonance (SPR) analysis and sent them to 
Strasbourg for inhibition and cocrystallization assays. For all further assays, the protein 
was produced and purified in our team. I established the purification protocol, 
performed cocrystallization assays and first aminoacylation tests to determine potential 
inhibition and the reaction conditions. Complementary inhibition analyses were 
realized in collaboration with Joëlle Rhudinger-Thirion from our team. 
 
12.2.1 Synthesis 
The library was designed with the following characteristics: a first AUG codon 
reprogrammed with an initiator tRNA N-(2-chloroacetyl)-(L or D)-tyrosine (L or D amino 
acid according to the name of the peptide), followed by a random region of 7 to 15 
NNK codons (where N represents any of the four bases and K represents either U or 
G) and terminated by a sequence coding the CGSGSGS peptide. Results of the 
selection are listed in Table 12-1.  
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Table 12-1 : Listing of selected peptides, with their name, sequence and mass over charge (m/z) 
for mass spectrometry identification. In the sequences, highlighted in yellow are the randomized 
sequences, in blue the terminal non-variable sequences and in green the unconventional amino 
acids. 
Name Sequence m/z 
D2 YQRSTRLLBYWCGSGSGS 1750.00 
D4 YKVWSLIRRRLVVCGSGSGS 1830.05 
L1 YWIAWLASHRLLIIHNCGSGSGS 2358.17 
L2 YKVWSLIRRRLVVCGSGSGS 1830.05 
L3 YLVVBBTPBHFTVSRKCGSGSGS 2148.11 
L4 YBFYLVQSWKLLFLSCGSGSGS 2172.08 
 
The first Y coding for N-(2-chloroacetyl)-(L or D)-tyrosine and the first cysteine 
of the non-variable sequence at the 3’-end are used for the macrocyclization reaction 
and the glycine-serine triple repeat is necessary for binding of puromycin (highlighted 
in blue in Table 12-1). Amino acid B corresponds to the unconventional amino acid 
biphenylalanine, encoded by the CAU codon (highlighted in green). Peptides were 
selected against the Pa-AspRS enzyme after biotinylation and binding on metal beads 
carrying streptavidin, following the procedure established in Suga’s team and 
described in several articles, such as Hayashi et al., 2012, Hipolito et al., 2013 and in 
section 12.1.  
After selection, SPR analysis with the Pa-AspRS and peptides was carried out 
to determine their binding affinity (except L1 which was unsuccessful due to its 
probable binding to the matrix). Results are presented in Figure 12-2. 
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For the five peptides tested, the KD value ranges from 23 to 350 nM, with L3 
exhibiting the best affinity.  
 
12.2.2 Inhibition assays 
To determine a potential inhibitory effect of the selected macrocyclic peptides 
towards Pa-AspRS enzymatic activity, aminoacylation assays in the absence and in 
the presence of the peptides were performed following the procedure schematically 
described in Figure 12-3 (for more details refer to Bonnefond et al., 2005).  
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The following molecules were used for aminoacylation assays: AspRS from 
Pseudomonas aeruginosa (Pa-AspRS), Escherichia coli (Ec-AspRS), Homo sapiens 
(Hs-AspRS) and tRNAAsp from Escherichia coli (Ec-tRNAAsp) as well as transcripts from 
Homo sapiens (Hs-tRNAAsp). Several couples AspRS:tRNA from different species 
were tested, with and without peptides. The first test was performed with the couple 
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Pa-AspRS:Ec-tRNAAsp and all peptides. According to the results, the peptides showing 
an inhibitory effect were tested on the couples Ec-AspRS:Ec-tRNAAsp and Hs-
AspRS:Hs-tRNAAsp to assess their specificity. During all aminoacylation tests, 
concentrations of every elements were kept constant except that of macrocyclic 
peptides. 1.2 μM tRNA, 1 μM AspRS and 32 μM Asp* C14 were used, peptides were 
varied from 0.4 to 40 μM. Results with the couple Pa-AspRS:Ec-tRNAAsp are presented 
in Figure 12-4, with the other couples in Figure 12-5. 
 
 
Figure 12-4 : Aminoacylation assays performed with the couple Pa-AspRS:Ec-tRNAAsp. 
Aliquots of the reaction mixture were taken out after 0/10/20/30 or 0/7/14/21 minutes, as 
indicated in each plot. Peptides were at 40 μM in the top two assays and at indicated 
concentrations in others. 
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 The first two plots present aminoacylation assays performed with all peptides at 
high concentration (40 μM). This allowed to determine that peptides L1, L3 and D2 
present an interesting effect, they reduced Pa-AspRS activity to respectively 10, 50 
and 40 percents. All further experiments were then performed with these peptides. The 
second step was to determine the minimal concentration at which they still showed an 
effect on aminoacylation efficiency (see three last plots from Figure 12-4). At 4 μM the 
same effect as at 40 μM was observed, but at 0.4 μM the effect was drastically reduced. 
Presented plots illustrate one assay but they were reproduced several times to 
determine KM and kcat values of the aminoacylation with and without peptides. 
Corresponding values are presented in Table 12-2. 
 
Table 12-2 : Summary of inhibition assays with peptides L1, L3 and D2.  
 Pa-AspRS:Ec-tRNAAsp 
Nativ + L1 at 2 μM + L3 at 2 μM + D2 at 2 μM 
Mean KM 0.3 μM 1.5 μM 1.6 μM 3.5 μM 
Mean kcat 30 min-1 22 min-1 32 min-1 33 min-1 
Number of 
independent 
assays 
2 6 3 4 
Conclusion / Increased KM 
(5x), slightly 
reduced kcat 
(1.3x) 
Increased KM 
(>5x), 
unchanged kcat 
Increased KM 
(>10x), 
unchanged kcat 
Inhibitor type / Competitive Competitive Competitive 
 
For comparison, the KM value published for the couple Ec-AspRS:Ec-tRNAAsp 
is 0.33 μM (Hasegawa et al. 1989), similar to what was measured for the couple Pa-
AspRS:Ec-tRNAAsp without peptide. All peptides induce an increase KM value and a 
slight or no effect on the kcat, indicating that they decrease the affinity of tRNA for 
AspRS but do not affect the speed of the reaction, which is characteristic of competitive 
inhibitors.  
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Following, assays were performed to assess peptides specificity by testing the 
E.coli and Human enzymes (Figure 12-5).  
 
 
Figure 12-5 : Aminoacylation assays performed with the couples Ec-AspRS:Ec-tRNAAsp, Pa-
AspRS:Ec-tRNAAsp and Hs-AspRS:Hs-tRNAAsp. Aliquots of the reaction mixture were taken 
out after 0/7/14/21 minutes. Peptides were used at 0.8 μM for Ec-AspRS and Pa-AspRS assays, 
at 40 μM for Hs-AspRS. 
 
For the first specificity assay, we wanted to test another bacterial AspRS and 
we choose the one from E. coli. Ec-AspRS and Pa-AspRS aminoacylation assays were 
performed once at the same time. The designed peptides also presented a slight effect 
on Ec-AspRS activity, thus we tried the human enzyme, which shares a lower 
sequence similarity with the P. aeruginosa enzyme. For the human enzyme, peptide 
concentration was increased to 40 μM, as for the first test with the P. aeruginosa 
enzyme. Results are presented in the bottom graph of Figure 12-5 and show that the 
designed peptides are not specific, they also inhibit the human enzyme. Therefore, it 
is likely that their biding site is close, if not directly in the catalytic site (whose sequence 
has been conserved during evolution), which would explain both their competitive 
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nature and the fact that they hardly distinguish the three AspRSs. In an attempt to 
confirm this hypothesis, I tried to co-crystallize the peptides with AspRS. 
 
12.2.3 Co-crystallization assays 
In the literature, the macrocyclic peptides designed with the RaPID selection 
process were also shown to be good cocrystallization partners, allowing easier 
crystallization (Hipolito et al. 2013; Tanaka et al. 2013) through the conformational 
stabilization of their target. In this optic, several cocrystallization assays from Pa-
AspRS with inhibitory peptides L1, L3 and D2 were performed using the commercial 
screens JCSG++ from Jena Bioscience and Index from Hampton Research. The Pa-
AspRS was used at 11 mg/mL in a ratio 1:1 with the peptides. Drops were prepared 
by mixing 150 and 100 nL of enzyme:peptide and crystallant volumes respectively, 
over a reservoir containing 60 μL with the help of a Mosquito Crystal pipetting robot 
(TTP Labtech, UK). One unique crystal, in form of a sea urchin, was observed with the 
protein alone in JCSG++ condition F10 (0.5% w/v Jeffamine ED-2001, 100 mM 
HEPES-NaOH and 1.1 M sodium malonat at pH 7.0) and presented diffraction spots 
up to 8 Å, but I never succeeded to reproduce it and crystal amount was not enough 
to perform microseeding. Tb-Xo4 was also even used as nucleant in screening assays 
but without success.  
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13 Microcin C 
13.1 Introduction to known AspRS inhibitors 
Recently, several compounds targeting aaRSs of P. aeruginosa were 
discovered by screening of synthetic library, as BT_03F04 and BT_04B09 against the 
GluRS (Hu et al. 2015) or BT02A02 and BT02C05 against the AspRS (Corona et al. 
2018). They are described as non-competitors inhibitors with respect of amino acids 
or tRNAs, exhibit specificity to the pathogen but a very moderate effect on P. 
aeruginosa cultures.  
General competitive inhibitors of AspRS, such as non-hydrolysable substrates 
analogs, have also been described. Figure 13-1 presents two of the most efficient 
inhibitors (Asp-AMS and Asp-ol-AMP) (Bernier et al. 2005), as well as the natural 
reaction intermediate, Asp-AMP and microcin C (McC) which is an inhibitor discovered 
in Enterobacteriaceae family. McC is produced by some strains to inhibit growth of 
surrounding competitors (Metlitskaya et al. 2006). In opposition to those presented 
before, these inhibitors are efficient on cultures but are both active on bacterial and 
human AspRSs.  
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Figure 13-1 : Chemical drawing of L-aspartyl adenylate, the reaction intermediate of tRNA 
aspartylation, and three non-hydrolysable analogs: 5’-O-[N-(L-aspartyl)sulfamoyl] adenosine 
(Asp-AMS), L-aspartol adenylate (Asp-ol-AMP) and the natural antibiotics microcin C (McC) 
(adapted from Claude Sauter). 
 
McC is very similar to Asp-AMP but possesses an amid instead of an acid 
anhydride linkage between the aspartyl and the AMP moities, which stabilizes the 
junction and make it non-hydrolysable. McC also has a peptide attached to the NH2 
function of aspartyl that allows it to penetrate target organisms through a membrane 
transporter. This peptide is cleaved after entry into sensitive cells by an 
aminopeptidase, allowing it to perform its activity as a non-hydrolyzable inhibitory 
analog (Severinov and Nair 2012). It has also an AMP part modified by a propylamine 
arm on the phosphate (Metlitskaya et al. 2009). The position of this arm and its function 
have never yet been precisely defined. This difference is the most notable with current 
synthetic AspRS inhibitors, Asp-AMS and Asp-ol-AMP. The mature form of McC 
without the small peptide is called McC*. McC has been further studied and modified, 
for example to allow inhibition of other synthetases, such as LeuRS and GluRS by 
changing the aspartate residue (Van De Vijver et al. 2009) or to modify cellular import 
as well as the entry process itself by altering the attached peptide sequence and length 
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(Bantysh et al. 2015). These inhibitors are not specific to bacteria and are therefore 
difficult to use as antibiotics as they may interact with enzymes in patients. 
  
At the beginning of my thesis, several datasets from Ec-AspRS soaked with McC* 
were already available. The McC* was provided by our collaborators from Paris (Prof. 
Sylvie Rebuffat, Musée National d’Histoire Naturelle). I performed data treatment and 
the best one is presented in section 13.2. In section 13.3, assays to collect data from 
the AspRS from Thermus thermophilus (Tt-AspRS) in complex with McC* are 
described.  
 
13.2 McC* in Ec-AspRS 
 
Ec-AspRS crystals were grown by vapor diffusion in 16% (m/v) PEG 6000, 1.6 
M NaCl and 100 mM Bis-Tris pH 7.0 with the protein at 20 mg/mL. The table 
summarizing statistics is presented below (Table 13-1). 
 
In this crystal form of the Ec-AspRS, three monomers are present in the 
asymmetric unit. McC* was only visible in one catalytic site when soaked 15 min in a 
drop with 2.5 mM McC*. Its position is well defined in the density map excepted for the 
propylamine arm. Still, it was positioned on one side of the phosphate due to steric 
clashes on the other side (Figure 13-2) but even the first carbon of the arm is not 
visible in the density. Two reasons could explain this fact:  
i) this arm is highly flexible and not involved in stable interactions, even in the 
catalytic pocket.  
ii) this arm was partially or totally degraded and is not present in the crystal. 
Following our results, our collaborators tested the molecule by mass spectrometry and 
concluded that their purified solution of McC* is composed of a mixture, with and 
without the propylamine arm. So we cannot conclude about this arm with the data we 
possess in Ec-AspRS.     
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Table 13-1 : Data collection and refinement statistics 
 Ec-AspRS soaked 15 min 
with 2.5 mM McC* 
X-ray beamline SLS - PXIII 
Wavelength (Å) 1.000 
Temperature (K) 100 
Detector Pilatus 2M 
Crystal-detector distance (mm) 300 
Oscillation (°  / s) 0.3 / 0.5 
No. of images 2400 
Space group C2 
a, b, c (Å) 118, 162, 132 
α, β, γ (°) 90, 110, 90 
Mosaicity (°) 0.13 
Resolution range (Å) 30 – 2.24 (2.38 - 2.34) 
Total No. of reflections 1467900 (207231) 
No. of unique reflections 109063 (16710) 
Completeness (%) 98.2 (90.6) 
Redundancy 13.5 (12.4) 
〈I/σ(I)〉 30.6 (3.5) 
Rmeas (%) 6.5 (81.3) 
CC1/2 (%) 100 (87.6) 
Overall B factor from Wilson plot (Å 2) 51.4 
No. of reflections, working set / test set 103604 / 5451 
Final Rcryst (%) / Rfree (%) 18.06 / 22.76 
No. of non-H atoms 14621 
R.m.s. deviations   
 Bonds (Å) 0.006 
 Angles (°) 0.935 
Ramachandran plot   
 Most favoured (%) 96.03 
 Allowed (%) 3.57 
Rotamer outliers (%) 2.31 
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13.3 Crystallization of Tt-AspRS 
 Due to the difficulty to produce good diffracting Ec-AspRS crystals, the model 
system to study McC* was switched to Thermus thermophilus AspRS (Tt-AspRS). 
Thermus possesses two distinct AspRSs, we choose to use AspRS-1 which is very 
similar to the E. coli enzyme (Becker et al. 1997; Ng et al. 2002). The expression and 
purification protocol was adapted from Poterszman et al., 1993 and Becker et al., 1997. 
Briefly, gene expression was induced with IPTG at 37°C in Escherichia coli (Rosetta 
2). Thanks to the thermostability of the Thermus enzyme, a first purification step could 
be performed by flocculating E. coli proteins by heating the cell extract 30 min at 70°C. 
This step was followed by ion-exchanged chromatography (DEAE) and size-exclusion 
chromatography (SEC), using Sephacel (BioRad) and Superdex 200 columns (GE 
Healthcare), respectively. The protein was finally concentrated using Amicon 50K 
(MILLIPORE) to the desired concentration and stored in 50 mM Tris-HCl, pH 7.5, 1 
mM DTT and 1 mM EDTA.  
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Several crystallization assays were performed with the purified enzyme, screening 
with the commercial kits JCSG++ from Jena Bioscience and Index from Hampton 
Research and optimization with already known conditions in sodium formate or 
ammonium sulfate and PEG 8000 (Zhu et al. 2001). As illustrated in Figure 13-3, 
crystals were obtained in absence and presence of agarose gel, but the maximum 
diffraction limit observed was only 2.8 Å, while we expected a resolution beyond 2 Å. 
Hence, another step of crystal quality optimization will be necessary before concluding 
this structural study of the binding of McC* and the orientation of its propylamine arm 
in AspRS catalytic site.  
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This thesis entitled “Application of new crystallization approaches and serial 
crystallography to the structural study of enzyme/tRNA complexes” was focused on 
two aspects, the first oriented towards crystallography and crystallogenesis and the 
second towards biologically relevant enzyme/tRNA complexes. The ChipX3 
microfluidic device (developed by Claude Sauter) and the Xtal Controller 900 
(developed by Xtal Concept, Hamburg, Germany) were used to assess their efficiency 
in several cases. Other methods that were available more broadly, such as trace 
fluorescent labeling (TFL, developed by Marc Pusey) and microseed matrix screening 
(MMS, developed by Allan D’Arcy) and the use of the crystallophore Tb-Xo4 
(developed by Eric Girard and Sylvain Engilberge) were implemented in the standard 
screening process of our team. All these devices, instruments and methods were used 
to study new macromolecules and ligands, including among others the CCA-adding 
enzyme from the psychrophilic bacterium P. halocryophilus (in collaboration with Prof. 
Mario Mörl), as well as several aspartyl-tRNA synthetases interacting with two family 
of inhibitors, the natural inhibitor microcin C (in collaboration with Prof. Sylvie Rebuffat) 
and macrocyclic peptides containing unconventional amino acids (in collaboration with 
Prof. Hiroaki Suga). 
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14 Biological aspects 
Aminoacyl-tRNA synthetases 
Aminoacyl-tRNA synthetases are essential enzymes involved in the first stages 
of protein synthesis. They are responsible for the transfer of amino acids, in the form 
of amino acid adenylate, to the 3’end of their cognate tRNA. My work led to the 
development of a purification protocol for Thermus thermophilus and Pseudomonas 
aeruginosa AspRSs, to ensure their quality and quantity, for crystallization assays and 
biochemical studies. Due to their highly essential and specific activity, these enzymes 
are potential good targets for drug design. Part of this thesis consisted in the 
characterization of two different types of inhibitors. The first one was microcin C (McC), 
a natural inhibitor produced by some E. coli strains to inhibit their surrounding 
competitors. This molecule is very similar to the natural aspartyl-adenylate natural 
substrate, the only differences consist in a nitrogen instead of an oxygen between the 
aspartyl and the adenylate to make it non-hydrolyzable and a propylamine arm on the 
phosphate. My structural study of the role of this arm in making McC specific for 
bacterial enzymes, was not conclusive with the E. coli AspRS. Further analysis of this 
inhibitor in complex with the T. thermophilus AspRS, an enzyme that is more stable 
and easy to handle, should help to improve the resolution of the complex and bring a 
clear answer to this question. The second family consists of macrocyclic peptides 
containing non-conventional amino acids. I selected six of them with the RaPID 
procedure for their binding properties to the AspRS of the pathogen P. aeruginosa and 
performed their characterization. Enzymatic tests indicated that three of the six 
selected peptides have an interesting inhibitory effect. Therefore I conducted a more 
detailed kinetic study of these inhibitors to find out that they are competitive inhibitors. 
Test with the E. coli and human enzymes revealed that these peptides are non-specific 
and thus would need further improvement to be used as drugs. I also tested them as 
co-crystallizing compound without obtaining crystals that would allow to solve the 
complex structure at high resolution. This enzyme has been resisting to crystallization 
since several years in our team and will require additional effort in the future to 
eventually determine its structure in the presence of peptidic inhibitors. 
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CCA-adding enzymes 
CCA-adding enzymes are other essential actors of tRNA life cycle, involved in 
the addition and the maintenance of the CCA sequence at the 3’ end of tRNAs. I 
included the enzyme from the psychrophilic bacterium P. halocryophilus in my set of 
model macromolecules for method development. This work led me to solve the 
crystallographic structure of the apo-enzyme and of the complex with the CTP 
substrate. These structures have been elucidated at high resolution (1.8 - 2 Å) in 
several chemical environments and by different crystallographic methods (molecular 
replacement and sulfur-SAD, at room or cryo-temperatures). The tests for co-
crystallization or soaking of the enzyme crystals with the ATP substrate have not been 
successful, which suggests that the latter does not bind alone but most probably 
requires the prior presence of tRNA. In addition, the study of the different structures at 
100 K compared to the available structures in the PDB of other bacterial organisms 
highlighted several cold adaptation features: the catalytic core in the N-terminus part 
does not show strong adaptation, compared to the C-terminus, which is responsible 
for tRNA binding and presents a significantly reduced α-helices content. It would be 
very interesting now to continue this project by solving the structure of the PhaCCA in 
complex with a tRNA or a mini helices (corresponding to the acceptor arm of a tRNA) 
at different stages of the CCA addition process. This could be performed by the study 
of static structures or by serial crystallography and the determination of the “molecular 
movie” by the use of XFEL radiation, thanks to sample preparation performed with the 
Xtal Controller (see below). Finally, another CCA-adding enzyme purified by our 
collaborators in Leipzig could be interesting to study. They discovered and managed 
to purify the enzyme from Romanomermis culicivorax, which is able to process the 
world smallest functional tRNAs, lacking the D- and T-arms (Wende et al. 2014; Jühling 
et al. 2018). The structure of this enzyme and the way it interacts with these peculiar 
tRNAs has never been described. Crystallization of the apo-form and of the complexes 
are in progress.   
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15 Crystallization and crystallographic aspects 
Several goals were achieved during this thesis in term of development and 
implementation of new crystallization approaches and serial crystallography.  
 
TFL, MMS and ChipX3 
 First, TFL and MMS were implemented in the laboratory with the PhaCCA 
project, following my participation in a FEBS course3, and led to several crystal 
structures at high resolution (de Wijn et al. 2018). These methods, which proved to be 
powerful and easy-to-use are now used in routine for other projects in our team.  
In addition, my work allowed to further demonstrate the advantages of the 
microfluidic ChipX3. Inside these chips, counter-diffusion crystallization experiments 
can be performed, allowing to screen a large panel of crystallizing agent concentrations 
in a convection-free environment. A previous study in our team presented a previous 
version of the chips with room-temperature (RT) data-collection on model proteins, as 
well as experimental phase determination using an ytterbium derivative (Pinker et al. 
2013). I was able to go further by demonstrating the compatibility of the device with 
microseeding, illustrating the easy detection of protein crystal by UV (with Tb-Xo4) and 
green light (after TFL), and carrying out serial crystallography RT data collection of 
“non-model” macromolecules. RT analysis are gaining popularity in our field, firstly by 
the success of recent structures obtained under XFEL radiation, but also more using 
conventional synchrotron radiation and this approach can be made easier by the 
ChipX3. In a study described in 2011 (Fraser et al. 2011) on a set of 30 proteins, they 
showed that in crystal cryo-cooled to 100 K more than 35% of amino acids side chains 
presented alternate conformations, thus advocating for analysis at RT, i.e. in more 
physiological conditions. The two articles presented in chapter II should help 
popularize these chips and the method of counter-diffusion in the community of 
crystallographers.  
 
                                                 
3 « Advanced methods in Macromolecular Crystallization VII » organized by the FEBS society in 2016 at Nové 
Hrady, Czech Republic. 
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Xtal Controller 
The Xtal Controller was acquired by the team shortly before the beginning of my 
thesis. It allows to control and follow-up a crystallization experiment in a closed 
chamber with an ultra-sensitive balance, two piezo-pump injectors, DLS and a camera. 
The initial purpose was the crystallization of difficult and/or sensitive cases, but more 
applications were recently imagined: the preparation of micro- and/or nanocrystalline 
samples for XFEL experiments, as well as the study of nucleation events and early 
crystal growth. My work allowed to define a precise experimental protocol for the use 
of this instrument and to test it for several purposes. As a result, the PhaCCA enzyme 
was crystallized and a dataset was collected at 1.85 Å. The instrument was also used 
to study the effect of Tb-Xo4 on nucleation and crystal growth of lysozyme and 
protease 1 from P. horikhoshii, leading to the observation of different types of 
behaviors.  
To precisely link a DLS profile obtained in the instrument to specific structures 
(nuclei, nanocrystals, microcrystals…), I performed preliminary tests to determine how 
to prepare a grid by negative staining to visualize these particles by transmission 
electron microcopy (TEM). The first assays were successful with fragmented PhaCCA 
crystals and are illustrated Figure 15-1. This observation of crystalline structures inside 
a solution are a prerequisite for the attribution of XFEL beamtime. Preparing samples 
for such kind of experiments is one of the future goals to achieve with support of the 
Xtal Controller. XFEL facilities, growing in number around the world, already proved 
their efficiency for high quality room-temperature data collection and time resolved 
crystallography, or production of molecular movies (Nango et al. 2016; Suga et al. 
2017; Johansson et al. 2017). To conclude, a scheme of the sample preparation for a 
mix-and-diffuse experiment at a XFEL installation is presented Figure 15-1. Crystals 
grown in the Xtal Controller could also be used for electron diffraction experiments, as 
this method is growing in terms of capacities (Clabbers et al. 2017, 2018). 
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Figure 15-1 : Schematic representation of an experimental protocol based on the Xtal Controller 
and electron microscopy to prepare a sample for time-resolved RT experiment under XFEL 
radiation. The middle panel corresponds to fragments of PhaCCA crystals observed by TEM 
after negative staining (scale bars = 50 µm) and the corresponding reciprocal lattices obtained 
by Fourier transform. Bottom panel is adapted from Stagno et al., 2017.  
Chapter VI Conclusions and perspectives 
 
166 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VII. Bibliographie 
Chapter VII Bibliographie 
 
168 
 
 
Adams PD, Afonine P V, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung 
L-W, Kapral GJ, Grosse-Kunstleve RW, et al. 2010. PHENIX: a comprehensive 
Python-based system for macromolecular structure solution. Acta Crystallogr D 
Biol Crystallogr 66: 213–21. 
Åqvist J. 2017. Cold Adaptation of Triosephosphate Isomerase. Biochemistry 56: 
4169–4176. 
Asherie N. 2004. Protein crystallization and phase diagrams. Methods 34: 266–272. 
Augustin MA, Reichert AS, Betat H, Huber R, Mörl M, Steegborn C. 2003. Crystal 
structure of the human CCA-adding enzyme: Insights into template-independent 
polymerization. J Mol Biol 328: 985–994. 
Bae E, Phillips GN. 2004. Structures and analysis of highly homologous psychrophilic, 
mesophilic, and thermophilic adenylate kinases. J Biol Chem 279: 28202–8. 
Baitan D, Schubert R, Meyer A, Dierks K, Perbandt M, Betzel C. 2018. Growing Protein 
Crystals with Distinct Dimensions Using Automated Crystallization Coupled with 
In Situ Dynamic Light Scattering. J Vis Exp. 
Bantysh O, Serebryakova M, Zukher I, Kulikovsky A, Tsibulskaya D, Dubiley S, 
Severinov K. 2015. Enzymatic Synthesis and Functional Characterization of 
Bioactive Microcin C-Like Compounds with Altered Peptide Sequence and Length. 
J Bacteriol 197: 3133–3141. 
Becker HD, Reinbolt J, Kreutzer R, Giege R, Kern D. 1997. Existence of two distinct 
aspartyl-tRNA synthetases in Thermus thermophilus. Structural and biochemical 
properties of the two enzymes. Biochemistry 36: 8785–8797. 
BERNAL JD, CROWFOOT D. 1934. X-Ray Photographs of Crystalline Pepsin. Nature 
133: 794–795. 
Bernard D, Akochy P, Beaulieu D, Lapointe J, Roy PH. 2006. Two residues in the 
anticodon recognition domain of the aspartyl-tRNA synthetase from 
Pseudomonas aeruginosa are individually implicated in the recognition of 
tRNAAsn. J Bacteriol 188: 269–74. 
Bernier S, Akochy P-M, Lapointe J, Chênevert R. 2005. Synthesis and aminoacyl-
tRNA synthetase inhibitory activity of aspartyl adenylate analogs. Bioorg Med 
Chem 13: 69–75. 
Betat H, Rammelt C, Mörl M. 2010. TRNA nucleotidyltransferases: Ancient catalysts 
Chapter VII Bibliographie 
 
169 
 
with an unusual mechanism of polymerization. Cell Mol Life Sci 67: 1447–1463. 
Blaise M, Bailly M, Frechin M, Behrens MA, Fischer F, Oliveira CLP, Becker HD, 
Pedersen JS, Thirup S, Kern D. 2010. Crystal structure of a transfer-
ribonucleoprotein particle that promotes asparagine formation. EMBO J 29: 3118–
29. 
Bonnefond L, Fender A, Rudinger-Thirion J, Giegé R, Florentz C, Sissler M. 2005. 
Toward the full set of human mitochondrial aminoacyl-tRNA synthetases: 
Characterization of AspRS and TyrRS. Biochemistry 44: 4805–4816. 
Briand C, Poterszman A, Eiler S, Webster G, Thierry JC, Moras D. 2000. An 
intermediate step in the recognition of tRNA(Asp) by aspartyl-tRNA synthetase. J 
Mol Biol 299: 1051–1060. 
Carter CW, Sweet RM. 1997. Macromolecular crystallography. Academic Press. 
Chernov AA. 1997. Crystals built of biological macromolecules. Phys Rep 288: 61–75. 
Clabbers MTB, Gruene T, Parkhurst JM, Abrahams JP, Waterman DG. 2018. Electron 
diffraction data processing with DIALS. Acta Crystallogr Sect D, Struct Biol 74: 
506–518. 
Clabbers MTB, van Genderen E, Wan W, Wiegers EL, Gruene T, Abrahams JP. 2017. 
Protein structure determination by electron diffraction using a single three-
dimensional nanocrystal. Acta Crystallogr Sect D, Struct Biol 73: 738–748. 
Corona A, Palmer SO, Zamacona R, Mendez B, Dean FB, Bullard JM. 2018. Discovery 
and Characterization of Chemical Compounds That Inhibit the Function of 
Aspartyl-tRNA Synthetase from Pseudomonas aeruginosa. SLAS Discov  Adv life 
Sci R D 23: 294–301. 
D’Arcy A, Bergfors T, Cowan-Jacob SW, Marsh M. 2014. Microseed matrix screening 
for optimization in protein crystallization: What have we learned? Acta Crystallogr 
Sect Struct Biol Commun 70: 1117–1126. 
D’Arcy A, Villard F, Marsh M, IUCr. 2007. An automated microseed matrix-screening 
method for protein crystallization. Acta Crystallogr Sect D Biol Crystallogr 63: 550–
554. 
De Maayer P, Anderson D, Cary C, Cowan DA. 2014. Some like it cold: Understanding 
the survival strategies of psychrophiles. EMBO Rep 15: 508–517. 
de Wijn R, Hennig O, Ernst FGM, Lorber B, Betat H, Mörl M, Sauter C. 2018. 
Combining crystallogenesis methods to produce diffraction-quality crystals of a 
Chapter VII Bibliographie 
 
170 
 
psychrophilic tRNA-maturation enzyme. Acta Crystallogr Sect FStructural Biol 
Commun F74: 747–753. 
Deutscher MP. 1990. Ribonucleases, tRNA nucleotidyltransferase, and the 3’ 
processing of tRNA. Prog Nucleic Acid Res Mol Biol 39: 209–40. 
Dick M, Weiergräber OH, Classen T, Bisterfeld C, Bramski J, Gohlke H, Pietruszka J. 
2016. Trading off stability against activity in extremophilic aldolases. Sci Rep 6: 
17908. 
Ducruix A, Giegé R. 1992. Crystallization of Nucleic Acid And Proteins. Oxford Univ 
Press 17: 255–288. 
Engilberge S, Riobé F, Di Pietro S, Lassalle L, Coquelle N, Arnaud CA, Pitrat D, 
Mulatier JC, Madern D, Breyton C, et al. 2017. Crystallophore: A versatile 
lanthanide complex for protein crystallography combining nucleating effects, 
phasing properties, and luminescence. Chem Sci 8: 5909–5917. 
Engilberge S, Riobé F, Wagner T, Di Pietro S, Breyton C, Franzetti B, Shima S, Girard 
E, Dumont E, Maury O. 2018. Unveiling the Binding Modes of the Crystallophore, 
a Terbium-based Nucleating and Phasing Molecular Agent for Protein 
Crystallography. Chem - A Eur J 24: 9739–9746. 
Eriani G, Delarue M, Poch O, Gangloff J, Moras D. 1990. Partition of tRNA synthetases 
into two classes based on mutually exclusive sets of sequence motifs. Nature 347: 
203–206. 
Ernst FGM, Erber L, Sammler J, Jühling F, Betat H, Mörl M. 2018. Cold adaptation of 
tRNA nucleotidyltransferases: A tradeoff in activity, stability and fidelity. RNA Biol 
15: 144–155. 
Ernst FGM, Rickert C, Bluschke A, Betat H, Steinhoff HJ, Mör M. 2015. Domain 
movements during CCA-addition: A new function for motif C in the catalytic core 
of the human tRNA nucleotidyltransferases. RNA Biol 12: 435–446. 
Feller G, Gerday C. 2003. Psychrophilic enzymes: Hot topics in cold adaptation. Nat 
Rev Microbiol 1: 200–208. 
Fernández-Millán P, Schelcher C, Chihade J, Masquida B, Giegé P, Sauter C. 2016. 
Transfer RNA: From pioneering crystallographic studies to contemporary tRNA 
biology. Arch Biochem Biophys 602: 95–105. 
Fitter J. 2005. Structural and dynamical features contributing to thermostability in α-
amylases. Cell Mol Life Sci 62: 1925–1937. 
Chapter VII Bibliographie 
 
171 
 
Fraser JS, van den Bedem H, Samelson AJ, Lang PT, Holton JM, Echols N, Alber T. 
2011. Accessing protein conformational ensembles using room-temperature X-ray 
crystallography. Proc Natl Acad Sci 108: 16247–16252. 
Garcia-Caballero A, Gavira JA, Pineda-Molina E, Chayen NE, Govada L, Khurshid S, 
Saridakis E, Boudjemline A, Swann MJ, Shaw Stewart P, et al. 2011. Optimization 
of protein crystallization: The opticryst project. Cryst Growth Des 11: 2112–2121. 
García-Ruiz JM. 2003. Counterdiffusion Methods for Macromolecular Crystallization. 
Methods Enzymol 368: 130–154. 
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16.3 Liste des stagiaires encadrés 
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semaines pour son mémoire de licence (« Bachelorarbeit »). 
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septembre 2017: membre du comité organisateur. 
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communication internationale, membre du comité pour les levées de fonds et 
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• Membre du bureau de l’association des doctorants internationaux de 
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17 Résumé détaillé en français 
 
Les aminoacyl-ARNt synthétases (aaRS) ainsi que les CCA ARNt nucléotidyl-
transférases (ou CCases) sont des enzymes essentielles qui participent aux premières 
étapes de la synthèse protéique ou traduction. Les CCases utilisent du CTP et de 
l’ATP comme substrats lors de la maturation des ARN de transfert (ARNt) pour former 
la queue CCA à leur extrémité 3’. En présence d’ATP, les aaRS activent un acide 
aminé sous forme d’adénylate et le lient à l’extrémité 3’ CCA de l’ARNt correspondant. 
Les aminoacyl-ARNt résultants sont ensuite transportés par les facteurs d'élongation 
au ribosome qui va incorporer les acides aminés aux chaînes polypeptidiques 
naissantes. 
De par leur caractère essentiel et leur spécificité de substrat, les aaRS constituent des 
cibles de choix pour la conception de médicaments. Une partie de mon travail a 
consisté en l’étude biochimique et la caractérisation structurale du mode de liaison de 
deux familles d’inhibiteurs des aspartyl-ARNt synthétases (AspRS) qui lient 
spécifiquement le L-aspartate. La première est représentée par un antibiotique naturel 
produit par certaines souches d’E. coli pour bloquer le site catalytique de l’AspRS de 
souches concurrentes (collaboration avec la professeure Sylvie Rebuffat du Musée 
National d'Histoire Naturelle, Paris) ; la seconde est une série de peptides synthétisés 
chimiquement qui ont été sélectionnés contre l’AspRS de l'agent pathogène humain 
opportuniste Pseudomonas aeruginosa (collaboration avec le professeur Hiroaki Suga 
de l’Université de Tokyo). 
Mon travail a mené à la mise au point d’un protocole de purification des AspRS de 
Thermus thermophilus et de P. aeruginosa, pour assurer leur qualité et leur quantité, 
et débuter la production de cristaux. J’ai fait le choix de travailler sur l’enzyme de T. 
thermophilus, analogue à celle d’E. coli mais plus stable et facile à manipuler, afin de 
réaliser l’étude structurale de l’antibiotique naturel produit par des souches d’E. coli.  
En parallèle des expériences de cristallisation, j’ai également caractérisé des peptides 
sélectionnés pour leurs propriétés de fixation à l’AspRS de P. aeruginosa. Les tests 
enzymatiques ont indiqué que quatre des six peptides sélectionnés avaient un effet 
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inhibiteur intéressant, j’ai donc mené une étude cinétique plus poussée de ces 
inhibiteurs. Cela m’a permis de caractériser l’inhibition et de définir des conditions de 
cristallisation en cours d’analyse pour une future optimisation de leur mode d’action et 
en vue d’essais d’inhibition sur culture cellulaire.  
J’ai également été impliqué dans un programme de coopération franco-allemand 
PROCOPE avec l'équipe du Professeur Mario Mörl (Université de Leipzig) portant sur 
l’étude structurale des CCases de différents organismes extrémophiles. Ceci m’a 
conduit à résoudre la structure cristallographique de l’enzyme de Planococcus 
halocryophilus, une bactérie psychrophile, capable de vivre à très basse température. 
En plus de la structure de l’apo-enzyme, j’ai également obtenu celle du complexe avec 
le substrat CTP. Ces structures ont été élucidées à haute résolution (1,8 – 2 Å) et par 
différentes méthodes cristallographiques (remplacement moléculaire et sulfur-SAD). 
Les tests de co-cristallisation ou de trempage des cristaux de l’enzyme avec le substrat 
ATP n’ont pas aboutis, ce qui montre que ce dernier ne se fixe pas seul mais nécessite 
très probablement la présence préalable de l’ARNt.  
Pour mener à bien ces études structurales, l’équipe de recherche s’est tournée vers 
une technologie innovante et une technologie plus rationnelle de préparation des 
cristaux de molécules biologiques appelée Xtal Controller 900 (Xtal-Concepts GmbH, 
Hambourg) ; elle permet de manipuler une goutte de cristallisation de quelques 
microlitres en jouant sur les concentrations de biomolécule et d'agent cristallisant 
(grâce à des microinjecteurs), tout en suivant l'évolution du système en direct par 
diffusion de la lumière (détection d'événements d'agrégation ou de nucléation, de 
formation de nanocristaux) et vidéo-microscopie (suivi de la croissance cristalline), le 
tout dans une enceinte thermostatée et à humidité contrôlée. 
L’enzyme CCase m’a aussi servi de cobaye pour la mise au point de méthodes et 
stratégies de cristallisation, mon objectif étant de continuer à améliorer la qualité des 
données structurales dont je dispose. Suite à ma participation à une école 
internationale, j’ai introduit au laboratoire deux méthodes qui ont montré leur efficacité 
: une méthode de marquage fluorescent des protéines (dite « Trace Fluorescent 
Labelling ») qui facilite l’identification de cristaux lors du criblage initial, ainsi qu’une 
méthode de microseeding (dite « Microseed Matrix Screening ») pour augmenter le 
nombre de conditions de cristallisation. J’ai aussi exploité un  nouveau concept de 
puces microfluidiques développées dans l’équipe pour déterminer la structure de 
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plusieurs macromolécules, dont la CCase, à température ambiante par l’approche de 
cristallographie sérielle. 
Comme je l’ai indiqué plus haut, notre équipe dispose de la dernière version du Xtal 
Controller. J’explore les possibilités qu'offre cette technologie pour l’étude de la 
cristallogenèse et un meilleur contrôle de la production de cristaux en vue de leur 
exploitation en biologie structurale. Ceci m’a conduit à étudier l’effet de différents 
agents cristallisants sur divers modèles protéiques, mais aussi d’un nouvel agent 
nucléant, un complexe de lanthanide facilitant la nucléation et la croissance de cristaux 
biologiques. Ces expériences se font sur de protéines d’intérêt biologique, dont ma 
CCase et des protéines fournis par nos collaborateurs (équipe du Dr Eric Girard à 
l’Institut de Biologie Structurale Grenoble), et j’ai pu  obtenir des cristaux pour plusieurs 
d’entre elles et les ai étudiés sous rayonnement synchrotron.
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 Raphaël DE WIJN 
Application des nouvelles 
approches de cristallisation et de cristallographie 
sérielle à l’étude structurale de complexes 
enzymes : ARNt 
 
 
Résumé en français 
Cette thèse porte sur deux aspects complémentaires, le développement et l’implémentation de 
nouvelles approches de cristallisation et de cristallographie sérielle ainsi que leur mise en oeuvre dans 
l’étude structurale de complexes enzymes : ARNt. La cristallographie est la méthode la plus employée 
en biologie structurale, mais elle présente encore des points délicats. Plusieurs méthodes avancées 
ont été déployées dans ce travail pour y pallier qui ont conduit à la résolution de la structure de l’ARNt 
nucléotidyltransférase du psychrophile Planococcus halocryophilus et à l’étude de son adaptation 
structurale au froid; des puces microfluidiques de cristallisation qui ont servi à la résolution de plusieurs 
structures à température ambiante par cristallographie sérielle; enfin le Xtal Controller utilisé pour 
l’étude d’évènements de nucléation et de croissance cristalline dans un but de préparation 
d’échantillons pour analyse sous rayonnement XFEL. Entre autres systèmes biologiques, cette thèse 
présente la caractérisation de deux familles d’inhibiteurs visant les aspartyl-ARNt synthétases, 
notamment du pathogène Pseudomonas aeruginosa. 
Mots clés :  
Biologie structurale ; Cristallographie sérielle ; Cristallogénèse ; Puces microfluidiques ; Xtal 
Controller ; Organisme psychrophile ; Organisme pathogène 
 
 
English abstract 
This thesis focuses on two complementary aspects, the development and implementation of new 
approaches of crystallization and of serial crystallography as well as their use in the structural study of 
enzymes/tRNA complexes. Crystallography is the most used method in structural biology, but it 
presents delicate points. Different methods were implemented in this work to overcome these points, 
which led to the resolution of the structure of the CCA-adding enzyme of the psychrophilic organism 
Planococcus halocryophilus and to the study of its structural adaptation to the cold; novel microfluidic 
crystallization chips that have been used for the resolution of several structures by serial 
crystallography at room-temperature; finally the Xtal Controller used for the study of nucleation and 
crystal growth events with the purpose of preparing samples for analysis under XFEL radiation. Among 
other biological systems, this thesis presents the study and characterization of two families of inhibitors 
targeting aspartyl-tRNA synthetases, including the one of the pathogenic organism Pseudomonas 
aeruginosa. 
Keywords : 
Structural biology ; Serial crystallography ; Crystallogenesis ; Microfluidic chips ; Xtal Controller ; 
Psychrophilic organism ; Pathogenic organism 
 
